anna suk-fong lok, m.d., f.r.c.p., agaf, faasld alice ...consulting positions page 15 visiting...

Anna Suk-Fong Lok 12/5/2016 1

Table of Contents

Anna Suk-Fong Lok, M.D., F.R.C.P., AGAF, FAASLD

Alice Lohrman Andrews Research Professor in Hepatology

Assistant Dean for Clinical Research

Professor of Internal Medicine and Director of Clinical Hepatology

Department of Internal Medicine

Division of Gastroenterology

University of Michigan Health System

1500 East Medical Center Drive

3912 Taubman Center, SPC 5362

Ann Arbor, MI 48109

Tel: 734-936-7511

Fax: 734-936-7392

[email protected]

Title and Contents

Education and Training Page 2

Certification and Licensure Page 2

Academic, Administrative, and Clinical Appointments Page 3

Research Interests Page 4

Grants Page 4

Honors and Awards Page 6

Memberships and Offices in Professional Societies Page 8

Editorial Positions, Boards, and Peer-Review Service Page 9

Teaching Page 11

Trainees Page 11

Committee, Organizational, and Volunteer Service Page 14

Consulting Positions Page 15

Visiting Professorships, Seminars, and Extramural Invited Page 16

Presentations

Bibliography Page 20

mailto:[email protected]


CURRICULUM VITAE

Anna Suk-Fong Lok, M.D.

Division of Gastroenterology

University of Michigan Health System

3912 Taubman Center, SPC 5362

Ann Arbor, MI 48109

Tel: 734-936-7511

Fax: 734-936-7392

[email protected]

Education and Training

09/1972-05/1977 M.B., B.S., University of Hong Kong School of Medicine, Hong Kong

11/1990 M.D., University of Hong Kong School of Medicine, Hong Kong

11/1983 MRCP, Royal College of Physicians, U.K.

09/1991 FRCP, Royal College of Physicians, Edinburgh, U.K.

POSTDOCTORAL TRAINING

07/1977-06/1978 Internship in Medicine and Surgery, Queen Mary Hospital, Hong Kong

10/1978-06/1980 Residency in Internal Medicine, Queen Mary Hospital, Hong Kong

07/1980-08/1981 Fellowship in Gastroenterology, Queen Mary Hospital, Hong Kong

11/1981-11/1983 Fellowship in Hepatology, Royal Free Hospital, London, U.K. (under

Prof. Dame Sheila Sherlock and Prof. Howard C. Thomas)

03/1984 Department of Microbiology and Immunology, University of California,

San Francisco, USA, in molecular biology techniques (under Prof. H.E.

Varmus)

08/1985 Department of Microbiology, University of Southern California, Los

Angeles, USA, in molecular biology techniques (under Dr. T.Y.K. Fung)

SENIOR POSTDOCTORAL TRAINING

08/1988-09/1989 Sabbatical leave (with Dr. J.L. Gerin) in Georgetown University,

Division of Molecular Virology and Immunology

Certification and Licensure

DEA# BL3081700

mailto:[email protected]


Michigan State L# 4301067002

Academic, Administrative and Clinical Appointments

Academic Appointments

10/1978-08/1981 Lecturer in Medicine, Department of Medicine, University of Hong Kong,

Queen Mary Hospital, Hong Kong

11/1981-11/1983 Hon Lecturer in Medicine, Academic Department of Medicine, Royal Free

Hospital, London, UK

12/1983-09/1987 Lecturer in Medicine, Department of Medicine, University of Hong Kong,


09/1987-08/1988 Senior Lecturer in Medicine, Department of Medicine, University of Hong

Kong, Queen Mary Hospital, Hong Kong

08/1988-08/1989 Visiting Associate Professor, Division of Molecular Virology and

Immunology, Georgetown University, Maryland, USA

09/1989-09/1990 Senior Lecturer in Medicine, Department of Medicine, University of Hong

Kong, Queen Mary Hospital, Hong Kong

09/1990-04/1992 Reader in Medicine, Department of Medicine, University of Hong Kong,


04/1992-06/1994 Associate Professor of Medicine, Tulane University School of Medicine,

Staff Physician, VA Medical Center, New Orleans, LA, USA

07/1994-09/1995 Professor of Medicine, Tulane University School of Medicine, Staff

Physician, VA Medical Center, New Orleans, LA, USA

10/1995-Present Professor of Internal Medicine, University of Michigan Medical Center,

Ann Arbor, MI, USA

Administrative Appointments

07/1996-08/2002 Medical Director of Liver Transplant Program, University of Michigan

Medical Center, Ann Arbor, MI, USA

10/1995-Present Director of Clinical Hepatology, University of Michigan Medical Center,

Ann Arbor, MI, USA

02/2008-08/2016 Associate Chair for Clinical Research, Department of Internal Medicine,

University of Michigan Medical Center, Ann Arbor, MI, USA

03/2016-Present Assistant Dean for Clinical Research, University of Michigan Medical

School, Ann Arbor, MI, USA

Clinical Appointments

10/1995-06/2001 Staff Physician, VA Medical Center, Ann Arbor, MI, USA


Research Interests

Dr. Lok’s clinical research is focused on the natural history and treatment of chronic hepatitis B

and C as well as prevention and early detection of hepatocellular carcinoma (HCC). Her

laboratory research is focused on the role of hepatitis B virus genotypes and molecular variants in

the pathogenesis of HBV-related liver disease and response to antiviral therapy, and the evolution

of antiviral drug-resistant HBV. The key areas of her current research are listed below:

Hepatitis B

Evaluation of new therapeutic agents for chronic hepatitis B

Role of HBV genotypes and molecular variants in pathogenesis of HBV-related liver disease and

response to treatment

Mechanisms of HBV-related HCC

Changing epidemiology of HBV infection in North America

Hepatitis C

Evaluation of new treatment for chronic hepatitis C

Evaluation of non-invasive assessment of hepatic fibrosis

Predictors of HCV progression

Epidemiology and natural history of chronic hepatitis C in the US and China and factors

contributing to differences in HCV-related HCC in the two countries

HCC

Evaluation of risk factors for HCC

Evaluation of biomarkers for detection of early HCC

Grants

Current (Direct cost; current year only)

2008-2020: NIH U01 DK082863 (+ 2 supplemental awards). Hepatitis B Clinical Research

Network Clinical Center: Michigan – Hawaii Consortium. $368,069 (Lok, PI and chair of

steering committee), 27% effort.

2012-2017: Bristol-Myers Squibb - A Long-Term Follow-up Study of Subjects Who Participated

in a Clinical Trial in which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) was

Administered for the Treatment of Chronic Hepatitis C. ~$25,000 (Lok, PI), <1% effort.

2012-2017: University of Florida – HCV-Target: Hepatitis C Therapeutic Registry and Research

Network – A longitudinal, observational study. ~$100,000 (Lok, PI), 1% effort.


2013-2018: Bristol-Myers Squibb: Predictors of HCV Progression. ~$130,000 (Lok, PI), 4%

effort.

2014-2017: Gilead: A long term follow-up registry study of subjects treated in a Gilead-

sponsored trial with chronic hepatitis B infection. ~$12,000 (Lok, PI) <1% effort.

2015-2018: PCORI PROP-up TARGET: The Patient-Reported Outcomes Project of HCV-

Target. ~$260,000 (Lok, coI; PI: Evon [UNC]), <1% effort.

2015–2019: VA CSR&D MERIT REVIEW. Does screening for HCC reduce HCC-related

mortality in HBV-infected Veterans? (Ioannou, PI), unpaid consultant.

2015-2019: 1R01CA196692-01, NIH/NCI. Does Screening for HCC in Cirrhotic Patients

Reduce HCC-related Mortality? (Ioannou, PI), unpaid consultant.

2016-2018: University of Michigan Health System-Peking University Health Sciences Center

Joint Institute for Clinical and Translational Research: Role of visceral adiposity and gut

microbiome in the pathogenesis of non-alcoholic fatty liver disease in lean versus obese patients:

a comparative study between patients at UMHS versus PUHSC. $145,000 (Lok, PI), 5% effort.

2015-2017: Gilead: A phase 3, global, multicenter, randomized, double-blind, placebo-controlled

study to investigate the safety and efficacy of sofosbuvir/velpatasvir/GS-9857 fixed-dose

combination for 12 weeks in direct-acting antiviral-experienced subjects with chronic HCV

infection. ~$50,000 (Lok, PI) 1% effort.

2015-2017: Gilead: A phase 3, global, multicenter, randomized, open label study to investigate

the safety and efficacy of sofosbuvir/velpatasvir/GS-9857 fixed-dose combination for 8 weeks

compared to sofosbuvir/velpatasvir for 12 weeks in direct acting antiviral-naïve subjects with

chronic HCV infection. ~$75,000 (Lok, PI) 1% effort.

2016-2017: Gilead: A phase 3, global, multicenter, randomized, open labeled study to investigate

the safety and efficacy of sofosbuvir/velpatasvir/GS-9857 fixed dose combination for 8 weeks

and sofosbuvir/velpatasvir for 12 weeks in subjects with chronic genotype 3 HCV infection and

cirrhosis. ~$40,000 (Lok, PI) <1% effort.

2016-2018: Gilead: A phase 3, global, multicenter, randomized, open label study to investigate

the safety and efficacy of sofosbuvir/velpatasvir/GS-9857 fixed dose combination for 12 weeks

and sofosbuvir/velpatasvir for 12 weeks in direct acting antiviral experienced subjects with

chronic HCV infection who have not received an NS5A inhibitor. ~$20,000 (Lok, PI) <1%


effort.

2016-2021: PCORI: PRIORITIZE STUDY: A pragmatic, randomized study of oral regimens for

hepatitis C: transforming decision-making for patients, providers and stakeholders. $123,150 (U

Florida: Nelson, PI, Lok co-I) 5% effort.

2016-2023: Target PharmaSolutions, Inc: A 5-year longitudinal observation study of patients

with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis. ~$120,000 (Lok PI) 1%

effort.

2013-2021: Gilead Sciences: A Long Term Follow-up Registry for Subjects Who Achieve a

Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic

Hepatitis C Infection. ~$12,000 (Fontana, PI, Lok co-I) <1% effort.

Mentee grants

2016-2018: American Association for the Study of Liver Diseases Foundation – Clinical and

Translational Research Award to Jessica Mellinger, MD (clinical lecturer), $75,000

Honors and Awards

1974 Janet McClure Kilborn Prize in Physiology and Biochemistry

1977 Distinctions in Medicine, Pediatrics, Obstetrics and Gynecology

1977 Gordon King Prize in Obstetrics and Gynecology

1977 RM Gibson Gold Medal in Pediatrics

1977 Chan Kai Ming Prize for the best performance in the final MB

examination

1977 Proxime Accessit to the Anderson Gold Medal for the second highest

aggregate score in all MB examinations

1977 Hong Kong University Alumni Association Prize for the most outstanding

graduate of the year

1985-1987 Young Investigator Award at the 1st, 2nd and 3rd Annual Scientific

Meetings of the Hong Kong Society of Gastroenterology

1990 Best Free Paper Award at the Annual Scientific Meeting of the Hong

Kong College of Physicians

1991 Sir Patrick Manson Gold Medal for outstanding M.D. Thesis

1992 First AJS McFadzean Memorial Lecture Prize, Combined Scientific

Meeting, Royal College of Physicians (London, UK) and Hong Kong

College of Physicians

1992-1993 Owl Club Award, Tulane University, for Outstanding Clinical Teacher

1996 Hugh R. Butt Award for Distinguished Achievement in Clinical Research

in Hepatology, American Digestive Health Foundation


1998 Lotus Award, University of Michigan, United Asian American Medical

Students Association for Outstanding Guidance and Support to Students

2001 Distinguished Physician Award, Chinese American Physician Society

2002 Singapore Ministry of Health Visiting Expert on Health Care and

Research in Liver Disease

2002 University of Texas Southwestern Medical Center, 6th

Annual Visiting

Professorship for an Outstanding Internationally Recognized Female

Scientist/Clinician/Health Care Worker.

2004 Lotus Award, University of Michigan, United Asian American Medical

Students Association for Outstanding Guidance and Support to Students

2005-2010 Bristol-Myers Squibb Foundation Freedom to Discover Virology Award

2005 Community Health Charities “Outstanding contribution to health” Award

in recognition of work on promoting awareness and education on

hepatitis B among Asian Americans through the THINK B Campaign

organized by the American Liver Foundation

2007 Outstanding Teacher Award, University of Michigan, Gastroenterology

Fellows, Class of 2007

4/2008 Distinguished Scientist Award, Hepatitis B Foundation

5/2008 Outstanding Women in Science, American Gastroenterological

Association Foundation

10/2008 Alice Lohrman Andrews Research Professor in Hepatology, University of

Michigan

6/2009 Outstanding Teaching Award, University of Michigan, Gastroenterology

Fellows, Class of 2009

9/2010 Okuda Award, Asian-Pacific Digestive Week (Kuala Lumpur, Malaysia)/

Journal of Gastroenterology and Hepatology

6/2011 League of Research Excellence, University of Michigan Medical School

6/2011 Scopus Award, Elsevier / International Digestive Disease Forum, Chinese

University, Hong Kong.

11/2011 Distinguished Service Award, American Association for Study of Liver

Diseases

3/2012 Distinguished Mentor Award, Michigan Institute of Clinical and Health

Research, University of Michigan (CTSA)

4/2012 Member, Association of American Physicians (inducted April, 2012)

10/2012 British Medical Association Book Award 2012 – First prize in Internal

Medicine Category

3/2013 Member, Clinical Excellence Society, University of Michigan Medical

School, Department of Internal Medicine

7/2013 Hepatitis Champion, Viral Hepatitis Action Coalition (CDC/HHS and

others), DC


8/2014 Thomson Reuters list of most-cited researchers in the world (top 1% by

citations in Web of Science database) for the period 2002-2012

9/2014 American Medical Association Women Physicians Section Inspirational

Physician Award

10/2015 Chinese Hospital, San Francisco, 42nd

Annual Distinguished Physician

Award

11/2015 American Liver Foundation, Distinguished Scientific Achievement Award

5/2016 American Gastroenterological Association, William Beaumont Prize in

Gastroenterology

Memberships and Offices In Professional Societies

1981-1995 Hong Kong Society of Gastroenterology

1985-1995 Gastroenterological Society of Australia

1986-1995 Asian Pacific Association for the Study of the Liver

1986-1995 International Association for the Study of the Liver

1987- European Association for the Study of the Liver

1988- American Association for the Study of Liver Diseases

1988- Hong Kong Association for the Study of Liver Diseases

1994- Southern Society for Clinical Investigation

1996- American Gastroenterology Association

American Association for the Study of Liver Diseases

1993-1996 Member, Publications Committee

1995-1996 Member, Abstract Selection Committee, Hepatitis non-C

1996-1998 Chair, Abstract Selection Committee, Hepatitis, non-C

1997 Member, Nomination Committee

1998-2000 Member, Abstract Selection Committee, Hepatitis B

1999-2001 Member, Clinical Research Committee

2000-2002 Chair, Abstract Selection Committee, Hepatitis B Treatments

2001-2003 Councilor at large, Governing Board

2004-2005 Member, International Educational Committee

2005-2009 Member, Abstract Selection Committee, Hepatitis B

2011-2013 Member, Abstract Selection Committee, Hepatitis B Treatment

2013-2015 Councilor, Governing Board

2014 Chair, Abstract Selection Committee, Hepatitis B Virology and

Pathogenesis

2016 President-elect

2017 President

National Institutes of Health


1996-1997 Member, Planning Committee, Consensus Development Conference on

‘Diagnosis and Management of Hepatitis C’, NIDDK

1996 NIAID, Collaborative Antiviral Study Group. Member, Hepatitis Advisory

Committee

1999-2000 Co-organizer, Advisory Workshop on ‘Management of Hepatitis B’,

NIDDK

2000 Member, Antiviral Resistance Task Force, NIAID

2004-2009 Member, Hepatitis Panel, US-Japan Medical Cooperative Program

2005-6 Co-organizer, Workshop on “Management of Hepatitis B – 2006”

2007 Member, Planning Committee, Consensus Development Conference on

“Management of Chronic Hepatitis B”, NIDDK

American Gastroenterology Association

1999-2000 Member, Committee on Women in Gastroenterology

2000-2003 Consultant, Gastroenterology Teaching Project on Viral Hepatitis

2006-2009 Member, AGA International Committee

2010-2013 Member, Research Award Panel

European Association for the Study of the Liver

1999 Member, Consensus Development Panel on Hepatitis C

2002 Member, Consensus Development Panel on Hepatitis B

American Liver Foundation

2004-2007 Member, National Board of Directors

2004-2007 Co-Chair, THINK B Program

2005-6 Chair, Hepatitis Council

Editorial Positions, Boards, and Peer-Review Service

Senior Associate Editor

2011-2012 Gastroenterology

Co-Editor

2007-2009 Journal of Viral Hepatitis

Associate Editor

2001-2006 Hepatology

Editorial Boards

1985-1993 Journal of Gastroenterology & Hepatology


1991-2001 Hepatology

2000- Journal of Hepatology

2001- Antiviral Therapy

2004- Liver Transplantation

2009-2010 Annals of Internal Medicine

2009-2011 Gastroenterology

Journal Review

Hepatology

Gastroenterology

Journal of Hepatology

American Journal of Gastroenterology

Journal of Medical Virology

Journal of Viral Hepatitis

Annals of Internal Medicine

New England Journal of Medicine

Gut

JAMA

Grant Review

1992 Ad Hoc Reviewer, N1DDK RO1 Award

1996- Ad Hoc Reviewer VA Merit Review Award

1997-1998 Ad Hoc Reviewer NIAID K08, RO3 Award

1997 Ad Hoc Reviewer, NCI, PO1

1998-2002 Member, Study Section on Microbiology and Infectious

Diseases, NIAID

1999 Ad Hoc Reviewer, NIDDK, RFA on Hepatitis C

2000 Ad Hoc Reviewer, NIDA, RFA on Hepatitis C

2000 Research Grant Council, Hong Kong

2001 Ad Hoc Reviewer, Special Review on CASG, NIAID

2001-2002 Ad Hoc Reviewer, Special Review on Hepatitis C and Liver Transplant,

NIDDK

2002 Ad Hoc Reviewer, Wellcome Trust, U.K.

2003 Ad Hoc Reviewer, NIDDK, RFA on Hepatitis C

2004-2009 American Liver Foundation, Research Grants Review Committee

2004- Reviewer, NIAID and NIDDK Loan Repayment Program

2004 Ad Hoc Reviewer, NIAID HIV Study Section

2004 Ad Hoc Reviewer, NIDDK, Hepatobiliary Pancreatic Study Section

2005 Ad Hoc Reviewer, NIAID, AIDS Clinical Trials Leadership Network

2007 Ad Hoc Reviewer, Wellcome Trust, UK


2009 Ad Hoc Reviewer, French National Cancer Institute

2009 Ad Hoc Reviewer, National Blood Service, UK

2009- Ad Hoc Reviewer, University and Polytechnic Grant Committee, Hong

Kong

2009 Ad Hoc Reviewer, NIDDK, ARRA Grants

2010 Ad Hoc Reviewer, NIDDK Hepatobiliary Pancreatic Study Section

2010 Chair, NIAID, Special Review – Novel therapies for bacterial and virus

infections

6/2011 Ad Hoc Reviewer, NIDDK, R21 panel

3/2012 Invited Reviewer, Danish National Technology Foundation

8/2011 Ad Hoc Reviewer, NIDDK, X01

3/2013 Ad Hoc Reviewer, VA HSR&D

8/2013 Ad Hoc Reviewer, NIDDK, X01

9/2013 Ad Hoc Reviewer, VA HSR&D

7/2015 Ad Hoc Reviewer, DOD grants on HBV



Teaching

1995- University of Michigan

Students:

Ambulatory clinics and attending rounds

Mentor:

UAAMSA 1996-

AMWA 1999-

Residents and Fellows:

Ambulatory clinics and attending rounds

Journal Clubs (4 times/year)

Case conferences (3 times/year)

In-Service lectures (6 / rounding month)

Morning Report (5/14, 4/15)

Others:

Medicine Grand Round (1/00, 8/11)

Lecture, University Health Service (4/97, 12/02, 1/03)

Course Co-Director and Lecturer AASLD Wrap-up (12/01, 11/02,

11/03, 12/04, 12/05, 12/06, 12/07, 12/08, 12/09, 12/10, 12/11, 12/12,

12/13, 12/14, 12/15, 12/16)

Lecturer, Liver Transplant Course (6/06, 4/07, 5/08, 5/09, 5/11, 5/12,

5/15)

Lecturer, General Medicine Morning conference (1/12)


Lecturer, Internal Medicine Course (5/15)

Lecturer, Metabolism and Endocrine conference (5/15)

Trainees

Tulane University

Ulus S. Akarca, M.D. – 1993-1994

1994. Recipient of American Federation of Clinical Research Trainee

Travel Award

1994. Glaxo-American Gastroenterology Association Trainee Research

Award

Hakan Bozkaya, M.D. – 1994-1995

Marc G. Ghany, M.D. – 1993-1996


Travel Award

1996. American Federation of Clinical Research Junior

Faculty Award 1996

Consuelo Soldevila-Pico, M.D. – 1993-1995


Travel Award

Balu Chandra, M.D. – 1994-1995


Travel Award

University of Michigan

Naresh Gunaratnam, M.D. – 1996-1998

Robert J. Fontana, M.D. – 1996-2002

Thomas Shehab, M.D. – 1996-2002

1998. Recipient of Senior Medical Resident Research Award

1998. Recipient of Department of Internal Medicine Research Day

Award

1998. Recipient of ACP, Michigan Chapter Residents Oral Presentation

Award

2000-2001 NIH T32 Training Program

2001-2002. AASLD/Schering Hepatology Fellowship

Henry LY Chan, M.B., B.S. – 1997-1998

Hong Kong Association for Study of Liver Diseases Fellowship

Eng-Kiong Teo, M.D. – 1999-2000

Singapore Government Fellowship

Khozema Hussain, M.D. – 1999-2000

Schering Plough Hepatology Fellowship

Chi-Jen Chu, M.D. – 2000-2002


Taiwan Government Fellowship

Jorge Marrero, M.D. – 2000-

2000-2001 AASLD Junior Faculty Award

2001-2003 AGA/ADHF Career Development Award

2001-2003 ACG Career Development Award (returned)

2001-2003 NIH K-30 trainee

2003-2004 University of Michigan/Pfizer Bridge Award for K30 graduate

2004-2009 NIH K23 award

Hari Conjeevaram, M.D. – 2001-2007


Mary Ann Huang, M.D. – 2001- 2005


2003-2004 AASLD/Schering Advanced Hepatology Fellowship

2003-2004 University of Michigan/Pfizer Bridge Award for K30 graduate

2004-2005 AASLD Jan Albrecht Clinical Research Award

Desmond C.T. Wai, M.D. – 2002-2003

Singapore Government Fellowship

Scott K. Fung, M.D. – 2003 -2005

2003-2004 Canadian Association for the Study of the Liver Fellowship

2004-2005 Hepatitis Foundation International Epidemiology Fellowship

Award

2004-2005 Canadian Institutes of Health Research Fellowship

Hee Bok Chae, M.D. – 2004-2005

2004-2005 Bristol-Myers Squibb Virology Fellowship

Caryn Baldauf, M.D. – 2004-2005

Emmanuelle Depayre Williams, M.D. – 2005-2006

Hellan Kang, M.D. – 2004-

NIH T32 Training Program

Hyung Joon Yim, M.D. – 2005-2006

Korean Fellowship

Stephen Wong, M.D. – 2005-6

Asia Brewery Medical Specialty Scholarship, Philippines

Bristol-Myers Squibb Virology Fellowship

Melissa Osborn, M.D. – 2005-6

Emory University, Infectious Diseases Section

Michael Volk, M.D. – 2005-2014

2006-2008 Robert Wood Johnson Clinical Scholars Program

2008-2011 AGA Foundation Research Scholar Award

2010 –2015, NIH K23 award

Pratima Sharma, M.D. – 2005-


NIH K30 / OJO trainee

NIDDK T32

American Transplant Society

2011 - NIH K08 award

Jessica Tan, M.D. – 2006-7

Singapore Ministry of Health and Changi General Hospital

Bulent Degertekein, M.D. – 2006 –8

2007-2008 Bristol Myers Squibb Foundation Virology Fellowship

Eric Orman, M.D. – 2007-9

Ed Chotiyaputta, M.D. – 2008-2010

Siriaj Hospital, Bangkok, Thailand

Eva Huang, M.D. – 2008-2013

Ravitz Foundation

Fausta Ditah, M.D. – 2009-2011

Chanunta Hongthanakorn, M.D. – 2009-2010

Military Hospital, Bangkok, Thailand

Andrew Tai, M.D., PhD – 2009-2014

2009-2011 AGA Research Scholar Award

2010- NIH K08 award

2013 – NIDDK R01

Mina Rakoski, M.D. – 2009-2015

NIH T32 Program

2011-2012 AASLD Advanced Hepatology Fellowship

2012-2013 AGA Emmet Keeffe Award

Cheng Wang, M.D. – 2011-2012

Alice Lohrman Andrews Research Professorship

Peng Hu, M.D. – 2012

Chung King Medical School, China

Suna Yapali, M.D. – 2012-4

Turkish Liver Association

Nizar Talaat, M.D. – 2012-4

Monica Konerman, M.D. – 2013 –

NIH T32 Program

Robert Wood Johnson Clinical Scholars Program

AASLD Advanced Hepatology Fellowship, 2015-2016

Jessica Mellinger, M.D. – 2013-

NIH T32 Program

Robert Wood Johnson Clinical Scholars Program

AASLD Advanced Hepatology Fellowship, 2014-5

AASLD Clinical and Translational Research Award, 2016-8


Arpan Patel, M.D. 2014-2015

AASLD Emerging Liver Scholar Award

Rima Mohamad, Pharm D 2014

Mary Thomson, M.D. 2015-

Aashesh Verma, M.D. 2015-

AASLD Emerging Liver Scholar Award

Tony Feng, M.D. 2016-

Elliot Tapper, M.D. 2016-

Committee, Organizational, and Volunteer Service

Memberships in Intramural Research Centers and Programs

1995- Member, Research Advisory Committee, Education Committee, Clinical

Operations Committee, Division of Gastroenterology

1996-2000 Member, Transplant Center Operating Committee

1997-2001 Member, Promotions Committee, Department of Internal Medicine

2006 Member, Leadership Panel, Med IRB Lean Project

2006 Member, IRBMED ICD Template Clinical Research Billing Work Group

2007 Member, Clinical Trials Grant Review Panel, CTSA

2009 Clinical Research Pricing Tool, Medical School Office of Research

2009-2010 Member, Advisory Panel, Strategic Assessment of Clinical Research

Enterprise, MICHR

2010-2013 Member, PTSP and KL2 grant review panel, CTSA/MICHR

2010 Member, Advisory Panel, eThority and Clinical Billing, Medical School

Office of Research

2010 Member, Geriatrics Division Internal Review, Department of Internal

Medicine

2010-2013 Member, Contracting Deployment Advisory Committee, Medical School

Office of Research / MICHR

2012-2016 Member, Advisory Panel, University of Michigan Office of Human

Research Compliance Review (OHRCR)

2014- Member (Chair 5/2016- ), Clinical Trials Task Force, University of

Michigan Medical School Research Board of Directors (RBOD)

2014- Member, Advisory Board, Veterans Education and Research Association

of Michigan (VERAM)

Community/Volunteer Service

1998-2004 Advisor, Michigan Hepatitis C Support Group

2000-2003 Co-Chair, Medical Advisory Board, Michigan Chapter, American Liver


Foundation

2005-2008 Advisor, PKIDS (Organization to Prevent Infectious Diseases in Children)

2006- Advisor, APAMSA (Asian Pacific American Medical Students

Association)

2006- 2012 Advisor, Healthy Asian Americans Program, School of Nursing,

University of Michigan

2006- Advisor, Asian Health Foundation

2008-2013 Member, Executive Board, Asian Health Foundation

Consulting Positions (Advisory Board, ad Hoc consulting, recent/active)

1998-2015 Gilead Sciences

2002-7, 2009-10 Bristol-Myers-Squibb

2003-2012 Hoffmann La Roche

2008-2013 Bayer (Data and Safety Monitoring Board)

2009-2015 GlaxoSmithKline (Hepatotoxicity Board)

2009-2010 Abbott (Data and Safety Monitoring Board)

2012 Achillon

2012 Astex

2012 Arrowhead

2012-2013 Janssen, Johnson & Johnson

2012-3, 2015 Merck

2012 Novartis

2013 Immune Targeting System

2013 MedImmune

2013-2015 Tekmira

Federal agencies, WHO and academic medical centers

2002 Consultant, Hepatitis B Antiviral Trials, FDA, CDER

2004 Consultant, Hepatitis B Immune Globulin in Liver Transplant Patients,

FDA, Biologics

2005- Member, External Advisory Board, Yale University Liver Center

2007- Consultant, CDC Viral Hepatitis Division

2011- Member, External Advisory Board, University of California San Francisco

Liver Center

2012-2015 Member, Hepatitis Guidelines Working Group, WHO, Geneva,

Switzerland

Visiting Professorships, Seminars, and Extramural Invited Presentations

State-of-the-art/Titled lectures


03/1992 First AJS McFadzean Memorial Lecture, Hong Kong

10/1994 State-Of-The-Art lecture, World Congresses of Gastroenterology,

Los Angeles, CA

1995 Xth

Charles Brown Memorial Lecture, Cleveland Clinic, Cleveland, OH

04/1996 IVth

British Liver Trust Lecturer, Birmingham, UK

11/1996 Key-note Speaker, First National Congress of Hepatology, Istanbul,

Turkey

1995 Plenary Lecture, IX Triennial International Symposium on Viral Hepatitis

and Liver Diseases, Rome Italy

1996 Keynote Speaker, 6th

National Symposium on Hepatitis B and C.

Melbourne, Australia.

1998 ‘State-of-the-Art’ Lecture on Treatment of Hepatitis B. 3rd

International

Symposium on Therapy of Liver Diseases, Barcelona, Spain.

1999 James Lau Memorial Lecture, 4th

International Symposium on Viral

Hepatitis and Liver Cancer, Shanghai, China

2000 Plenary Lecture, X Triennial International Symposium on Viral Hepatitis

and Liver Diseases, Atlanta, GA

2001 Mizne Lecture, McGill University, Montreal, Canada

2002 6th

Annual Lectureship – Distinguished Women in Science/Medicine,

UTSW, Dallas, TX

2003 Plenary Lecture, XI Triennial International Symposium on Viral Hepatitis

and Liver Diseases, Sydney, Australia

2003 Stephen Winter Memorial Lecture – University of Illinois, Chicago

2004 AASLD State-of-the-art-lecture, DDW, New Orleans, LA

2005 Sheila Sherlock Liver Research Day Guest Speaker, University of Toronto,

Toronto, Canada

2006 State of the art lecture, Annual Hepatitis Symposium, Greek Liver

Association, Athens, Greece

2007 21st Klatskin lecture, Yale University, New Haven, CT

2008 14th

Leon Schiff lecture, University of Miami, Miami, FL

9/2010 Okuda Lecture, Asian Pacific Digestive Week, Kuala Lumpur, Malaysia

6/2011 1st Scopus Lecture, International Digestive Forum, Hong Kong

5/2012 AASLD State of the Art Lecture – Hepatitis B: Who to treat and Who can

wait? DDW, San Diego, CA

10/2012 27th Leon Schiff Lecture – Hepatitis B Treatment, University of

Cincinnati, Cincinnati, OH

11/2012 President’s Choice Lecture – Progress in Hepatitis B: A journey from 1982

to 2012, 63rd

AASLD annual meeting, Boston MA

10/2014 Wade Volwiler Visiting Professor, lecturer at Medicine Grand Rounds –

Hepatitis B Progress and GI Grand Rounds – Lessons learned from


Hepatitis B Research Network, University of Washington, Seattle, WA

12/2014 William and Rebecca Balistreri Lecturer – Hepatitis C Cure, How to

Apply the Tools we Have, Cincinnati Children Hospital, Cincinnati, OH

2/2015 Andres Blei Memorial Lecturer – Towards Global Elimination of Hepatitis

B, Northwestern University, Chicago, IL

4/2015 Fenton Schaffner Lecturer – New lessons about an ancient disease:

Lessons learned from Hepatitis B Research Network, Mount Sinai Icahn

School of Medicine, New York, NY

5/2015 Raj and Prem Goyal Lecturer – Implementation of Hepatitis C Cure.

Boston VA Medical Center, Boston, MA

5/2016 Pfeiffer Diversity Visiting Professor – Progress in Hepatitis B - Stanford

University Medical School, Palo Alto, CA

11/2016 Leon Schiff State-of-the-art Lecture – Elimination of hepatitis B: is it

possible? American Association for the Study of Liver Diseases Annual

Meeting, Boston, MA

12/2016 8th

Reynolds Memorial Lecturer – Treatment of hepatitis B: current status

and prospects for cure - University of Southern California, Los Angeles,

CA

National (from 2011)

1/2011 Moderator and Invited Speaker, AGA Clinical Congress, Miami, FL

1/2011 Visiting Professor and GI Grand Rounds Speaker, University of Colorado,

Aurora, CO

2/2011 Invited Speaker, American Chinese Medical Association Annual Scientific

Meeting, Boston, MA

4/2011 Invited Speaker, Medicine Grand Rounds, Bronson Hospital, Kalamazoo,

MI

6/2011 Course Director, moderator and speaker, AASLD-CDC Single Topic

Conference on Viral Hepatitis, Atlanta, GA

11/2011 Invited Speaker, Postgraduate Course; and Moderator, Parallel Free Paper

Session, AASLD Annual Meeting, San Francisco, CA

12/2011 Invited Speaker and Moderator, HepDart, Kauai, HI

1/2012 Invited Speaker and Moderator, AGA Clinical Congress, Miami, FL

2/2012 Invited Speaker, GI/Liver Conference, Honolulu, HI

3/2012 Invited Speaker, Medicine Grand Rounds, and ID Conference, University

of Massachusetts, Worcester, MA

3/2012 Invited Speaker, Grand Rounds, Antiviral and Drug Hepatotoxicity

Divisions, FDA, Silver Spring, MD

3/2012 Invited Speaker, Scripps Clinic Liver Course, La Jolla, CA


4/2012 Invited Speaker, Medicine Grand Rounds, Bronson Hospital, Kalamazoo,

MI

5/2012 Invited Speaker, DDW Postgraduate Course and Moderator, DDW

Clinical Challenge Session, San Diego, CA

5/2012 Invited Speaker, GI Grand Rounds, University of Connecticut,

Farmington, CT

7/2012 Invited Speaker, Symposium on HCV Direct Acting Antivirals, San

Francisco, CA

9/2012 Invited Speaker, GI Conference, Stanford University, Palo Alto, CA

11/2012 Invited Speaker, Postgraduate Course, and President’s Choice Lecture,

AASLD annual meeting, Boston, CA

1/2013 Invited Speaker, AGA Clinical Congress, San Diego, CA

1/2013 Lecturer, Web lecture, Charles B. Wang Community Health Center, New

York, NY

2/2013 Invited Speaker, GI Conference, University of Chicago, Chicago, IL

2/2013 Invited Speaker, Update in Hepatology, University of Miami, Miami, FL

2/2013 Lecturer, Web lecture, VA Health System, national

3/2013 Invited Speaker and Moderator, AASLD Emerging Trends Conference on

Reactivation of Hepatitis B, Crystal City, VA

4/2013 Invited Speaker, UCSF Liver Center Annual Meeting, San Francisco, CA

4/2013 Invited Speaker, GI Grand Rounds and Research Forum, Baylor University

Medical Center, Houston, TX

4/2013 Invited Speaker, Medicine Grand Rounds, MD Anderson Medical Center,

Houston, TX

5/2013 Invited Speaker, Liver Update, Yale University, Westport, CT.

5/2013 Invited Speaker, Postgraduate Course, Digestive Disease Week, Orlando,

FL.

12/2013 Invited Speaker and Moderator, HepDart Symposium, Kona, HI

3/2014 GI and Liver Symposium, Virginia Commonwealth University, Richmond,

VA

4/2014 Invited Lecturer, Medicine Grand Rounds, Bronson Hospital, Kalamazoo,

MI

5/2014 Invited Speaker, International Conference on Antiviral Resistance,

Raleigh, NC

10/2014 Invited Speaker, Seattle Gut Club, Seattle, WA

11/2014 Invited Speaker, Liver Symposium, Brooklyn, NY

1/2015 Invited Speaker, ASCO GI Cancer Symposium, San Francisco, CA

3/2015 Invited Speaker, GI/Liver Update, University of Pennsylvania,

Philadelphia, PA

10/2015 Invited Speaker, Annual Distinguished Awardee Lecture, Chinese


Hospital, San Francisco, CA

10/2015 Invited Speaker, Liver Symposium, Loma Linda University, Palm Springs,

CA

11/2015 Moderator – Postgraduate Course and Late Breaker session, Invited

Speaker – Hepatology Associates Course and HBV Special Interest Group

Symposium, AASLD Annual Meeting, San Francisco, CA

12/2015 Invited Speaker, Academy of Medicine Conference on Hepatitis B and C,

Washington, DC.

12/2015 Invited Speaker and Moderator, HepDART symposium, Maui, HI

3/2016 Moderator, AGA-AASLD Academic Skills Workshop, Phoenix, AZ

3/2016 Invited Speaker, GI Grand Rounds, Cleveland Clinic, Cleveland, OH

5/2016 Invited Speaker and Moderator, Digestive Diseases Week, San Diego, CA

8/2016 Invited Speaker, GI Grand Rounds, Indiana University, Indianapolis, IN

9/2016 Course Director, Moderator and Speaker, AASLD-EASL HBV Treatment

Endpoint Workshop, Alexandria, VA

9/2016 Invited Speaker, AASLD Liver Transplant Board Review Course,

Chicago, IL

11/2016 Moderator and Speaker, AASLD Annual meeting, Boston, MA

International (from 2011)

2/2011 Moderator and co-Director, Cost-effectiveness of HBV Treatment

Workshop, APASL annual meeting, Bangkok, Thailand

3/2011 Invited Speaker and Moderator, Professor Howard Thomas Festschrift,

Imperial College & St. Mary’s Hospital, London, UK

3/2011 Invited Speaker, Virgil Symposium, EASL annual meeting, Berlin,

Germany

6/2011 Invited Speaker and moderator, International Digestive Disease Forum,

Hong Kong

9/2011 Invited Speaker, International Liver Cancer Association, Hong Kong

9/2011 Moderator, International Symposium on Therapy in Liver Diseases,

Barcelona, Spain

11/2011 Invited Speaker, Update in Hepatology, Milan, Italy

2/2012 Invited Speaker and Moderator, APASL annual meeting, Taipei, Taiwan

4/2012 Invited Speaker, HBV Symposium and Highlights of 2011, EASL annual

meeting, Barcelona, Spain

6/2012 Invited Speaker, Hepatitis Conference, St. Petersburg, Russia

6/2012 Plenary Speaker, 14th

Triennial Symposium on Viral Hepatitis and Liver

Disease, Shanghai, China

6/2012 Invited Speaker, Hepatitis C Conference, Peking University, Beijing,


China

7/2013 Invited Speaker, Conference celebrating 50th

anniversary of discovery of

HBsAg, Peking University, Beijing, China

7/2013 Invited Speaker, Changing Landscape of HCV Treatment, 302 Hospital,

Beijing, China

8/2013 Invited Speaker, Liver Symposium and DS Chen Retirement Festschrift,

Taiwan Association for the Study of the Liver, Taipei, Taiwan

10/2013 Invited Speaker, Liver Symposium and EJ Heathcote Retirement

Festschrift, University of Toronto, Toronto, Canada

4/2014 Invited Speaker, HBV and HCV Symposium, EASL annual meeting,

London, UK

6/2014 Invited Speaker, 2014 Liver Week, Joint Symposium of Korean

Association for the Study of the Liver, Korean Hepatobiliary Surgery

Society, Korean Liver Transplantation Society and Korean Liver Cancer

Society, Jeju Island, Korea

7/2014 Invited Speaker, HCV Symposium, WHO (China)-Chinese Medical

Society-Chinese Society of Hepatology, Beijing, China

9/2014 Invited Speaker, Special Conference on HBV, EASL-APASL Symposium,

Athens, Greece

12/2014 Invited Speaker, APASL Single Topic Conference on Hepatitis B,

Guangzhou, China

3/2015 Moderator and Invited Speaker, APASL Annual Meeting, Istanbul, Turkey

3/2015 Invited Speaker, Hepatology Symposium, Bogota, Colombia

6/2015 Invited Speaker, State of the art lecture, Global Summit on Viral Hepatitis,

Berlin, Germany

7/2015 Co-organizer and invited speaker, Inaugural meeting on Highlights of

2014 AASLD Meeting, sponsored by Chinese Society of Hepatology and

endorsed by AASLD, Beijing and Shanghai, China

9/2015 Moderator, Symposium on Therapy in Liver Diseases, Barcelona, Spain

10/2015 Invited Speaker, AGA-Hangzhou Joint GI meeting, China

2/2016 Invited Speaker and Moderator, APASL Annual Meeting, Tokyo, Japan

4/2016 Invited Speaker and Moderator, EASL International Liver Congress,

Barcelona, Spain

5/2016 Moderator, ANRS Symposium on HBV Cure, Paris, France

6/2016 Invited Speaker and Moderator, APASL Single Topic Conference on

Hepatitis C, Kaohsiung, Taiwan

6/2016 Co-organizer, speaker and moderator, AASLD-Chinese Society of

Hepatology Conference on AASLD meeting highlights, Beijing, China

6/2016 Invited Speaker, Annual Meeting of the Mexican Society of Hepatology,

VeraCruz, Mexico


9/2016 Invited Speaker, Biennial Meeting, Latin American Society of Hepatology

(ALEH), Santiago, Chile

12/2016 Invited Speaker, APASL Single Topic Conference on HBV, State of the

art lecture, Beijing, China

Bibliography

Peer-Reviewed Publications

1. Lee PK, Lai CL, Lok ASF, Tse TF, Lai KN, Chow SF and Lam KC. Haemodynamic

responses to intravenous cimetidine in subjects with normal lung function and in subjects

with chronic airway obstruction. Brit J Clin Pharmacol 11:339-343, 1981. PMCID:

PMC1401670/

2. Lai CL, Ng RP and Lok ASF. The diagnostic value of the ratio of serum gamma

glutamyl transpeptidase to alkaline phosphatase in alcoholic liver disease. Scand J

Gastroent 17: 41-47, 1982.

3. Reshef R, Lok ASF and Sherlock S. Cholestatic jaundice in fascioliasis treated with

niclofolan. Brit Med J 285:1243-4, 1982. PMCID: PMC1499778.

4. Wu PC, Lai CL, Lok ASF and Lin HJ. An ultrastructural analysis of hepatocellular

carcinoma. Cancer 2:504-507, 1983.

5. Weller IVD, Karayiannis P, Lok ASF, Montano L, Bamber M, Thomas HC and Sherlock

S. The significance of delta agent infection in chronic hepatitis B virus infection in Great

Britain. Gut 24:1061-3, 1983. PMCID: PMC1420126.

6. Lok ASF, Weller IVD, Karayiannis P, Brown D, Fowler MJF, Monjardino J, Thomas HC

and Sherlock S. Thrice weekly lymphoblastoid interferon is effective in inhibiting

hepatitis B virus replication. Liver 4:45-49, 1984.

7. Fowler MJF, Monjardino J, Weller IVD, Lok ASF and Thomas HC. An analysis of the

molecular state of HBV-DNA in the liver and serum of patients with chronic hepatitis and

primary liver cell cancer and the effect of treatment with adenine arabinoside. Gut

25:611-18, 1984. PMCID: PMC1432367.

8. Lok ASF, Farci P and Thomas HC. Epidemiology and clinical course of delta infection

in Britain. In Delta Infection and Viral Hepatitis, ed Verme G, Bonino F and Rizzetto M,

Alan R Liss, Inc.; pp 219-24.


9. Lok ASF, Wilson LA and Thomas HC. Neurotoxicity associated with adenine

arabinoside monophosphate in the treatment of chronic hepatitis B virus infection. J

Antimicrob Chemother 14:93-9, 1984.

10. Novick DM, Lok ASF and Thomas HC. Diminished responsiveness of homosexual men

to antiviral therapy in HBsAg positive chronic liver disease. J Hepatol 1:29-35, 1984.

11. Lok ASF, Hadziyannis SJ, Weller IVD, Karvountzis MG, Karayiannis P, Monjardino J,

Montano L and Thomas HC. The contribution of low level HBV replication to

continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B

virus infection. Gut 25:1283-7, 1984. PMC1432328

12. Lai CL, Wu PC, Wong KL and Lok ASF. Clinical features of ulcerative proctocolitis in

Hong Kong Chinese: a review of three decades. Am J Proctology, Gastroenterology,

Colon and Rectal Surgery 36:14-9, 1985.

13. Karayiannis P, Goodall AH, Waters JA, Galpin S, Lok ASF, Thorp R and Thomas HC.

Clinical Evaluation of a monoclonal assay for hepatitis B surface antigen: identification

of “HBsAg-like” polypeptides non reactive in conventional radioimmunoassays. J Med

Virol 15:291-303, 1985.

14. Karayiannis P, Fowler MJF, Lok ASF, Greenfield C, Monjardino J and Thomas HC.

Detection of serum HBV-DNA by molecular hybridization: correlation with HBeAg/anti-

HBe status, racial origin and liver histology. J Hepatol 1:99-106, 1985.

15. Dunk AA, Scott SC, Johnson PJ, Melia W, Lok ASF, Murray Lyon I, Williams R and

Thomas HC. Mitozantrone as a single agent therapy in hepatocellular carcinoma. A

Phase III Study. J Hepatol 1:395-404, 1985.

16. Lok ASF, Lindsay I, Scheuer PH and Thomas HC. Clinical and histological features of

delta infection in chronic hepatitis B virus carriers. J Clin Pathol 38:530-3, 1985.

PMC499203

17. Weller IVD, Lok ASF, Mindel A, Karayiannis P, Galpin S, Monjardino J, Sherlock S and

Thomas HC. A randomized, controlled trial of adenine arabinoside 5'-monophosphate in

chronic hepatitis B virus infection. Gut 26:745-51, 1985. PMC1433015.

18. Karayiannis P, Novick DM, Lok ASF, Fowler MJF, Monjardino J, Thomas HC. Hepatitis

B virus DNA in saliva, urine and seminal fluid of carriers of hepatitis B e antigen. Br


Med J 290: 1853-5, 1985. PMC1416807.

19. Lok ASF, van Leeuwen DJ, Thomas HC and Sherlock S. Psychosocial impact of chronic

infection with hepatitis B virus on British patients. Genitourin Med 61:279-82, 1985.

PMC1011831.

20. Lok ASF, Karayiannis P, Jowett TP, Fowler MJF, Farci P, Monjardino J and Thomas HC.

Studies of HBV replication during acute hepatitis followed by recovery and acute

hepatitis progressing to chronic disease. J Hepatol 1:671-9, 1985.

21. Wong KL, Lai CL, Wu PC, Hui WM, Wong KP and Lok ASF. Ultrasonic Studies in

Hepatic Neoplasm: patterns and comparisons with contrast radiological studies. Clin

Radiology 36:511-5, 1985.

22. Lam SK, Lau WY, Lai CL, Lee NW, Poon GP, Hui WM, Lok ASF, Ng MMT, Fok KH,

Yu HC. Efficacy of sucralfate in corpus, prepyloric, and duodenal ulcer - associated

gastric ulcers: a double-blind, placebo controlled study. Am J Med 79 (2C):24-31, 1985.

23. Lok ASF, Novick DM, Karayiannis P, Dunk AA, Sherlock S and Thomas HC. A

randomized study of the effects of adenine arabinoside 5'-monophosphate (short or long

courses) and lymphoblastoid interferon on hepatitis B virus replication. Hepatology

5:1132-8, 1985.

24. Lam SK, Lau WY, Choi TK, Lai CL, Lok ASF, Hui WM, Ng MMT, Choi SKY.

Prostaglandin E1 (Misoprostol) overcomes the adverse effect of chronic cigarette

smoking on duodenal ulcer healing. Dig Dis Sci 31: 68S-74S, 1986.

25. Fowler MJF, Greenfield C, Chu CM, Karayiannis P, Dunk A, Lok ASF, Lai CL, Teo EK,

Monjardino JP, Wankya BM, Thomas HC. Integration of HBV-DNA may not be a pre-

requisite for the maintenance of the state of malignant transformation - An analysis of

110 liver biopsies. J Hepatol 2:218-29, 1986.

26. Lok ASF, Lai CL, Wong KL and Lam WK. Intrahepatic cholestasis associated with

enlarged gallbladder. Med J Aust 145:36-7, 1986.

27. Lok ASF, Lai CL, Wu PC, Ng MMT. Response to Hepatitis B Vaccine in Family

Members of HBsAg Carriers. J Med Virol 19:33-9, 1986.

28. Lok ASF, Lin HJ, Wu PC, Lai CL. Serum bile acids and other liver function tests in

patients with chronic hepatitis B treated with interferon: an interim report. Proceedings


from the Second International Symposium on Bile Acids in Hepatobiliary and

Gastrointestinal Diseases. IRL Press, Oxford pp 85-9, 1986.

29. Lok ASF, Wong KP, Lee PK, Chiu KW, Mok CK, Lam SK. Radiological Diagnosis of

Leiomyosarcoma of the Inferior Vena Cava. Clin Radiol 37:403-5, 1986.

30. Hui WM, Lam SK, Lok ASF, Ng MMT, Wong KL, Fok KH. Sulpiride improves

functional dyspepsia - a double blind, controlled study. J Gastroenterol Hepatol 1:391-

400, 1986.

31. Hui WM, Lam SK, Ho J, Ng MMT, Lui I, Lai CL, Lok ASF, Lau WY, Poon GP, Choi S,

Choi TK. Chronic antral gastritis in duodenal ulcer-natural history and treatment with

prostaglandin E. Gastroenterol 91:1095-101, 1986.

32. Novick DM, Brown DJC, Lok ASF, Lloyd C, Thomas HC. Influence of sexual

preference and chronic hepatitis B virus infection on T lymphocyte subsets, natural killer

activity and suppressor cell activity. J Hepatol 3:371-7, 1986.

33. Lok ASF, Lai CL, Wu PC. Interferon therapy of chronic hepatitis B virus infection in

Chinese. J Hepatol Vol 3 (Suppl 2): S209-S215, 1986.

34. Lok ASF, Lai CL, Wu PC, Leung EKY, Lam TS. Spontaneous Hepatitis B e Antigen to

Antibody Seroconversion and Reversion in Chinese Patients with Chronic Hepatitis B

Virus Infection. Gastroenterol 92:1839-43, 1987.

35. Lok ASF, Lai CL, Hui WM, Ng MT, Wu PC, Lam SK, Leung EKY. Absence of

transmission of hepatitis B by fibreoptic upper gastrointestinal endoscopy. J

Gastroenterol Hepatol 2:175-80, 1987.

36. Lam SK, Hui WM, Lau WY, Branicki FJ, Lai CL, Lok ASF, Ng MMT, Fok PJ, Poon GP,

Choi TK. Cigarette smoking affects healing and relapse of cimetidine treated but not

sucralfate - treated duodenal ulcer. Gastroenterol 19:1193-1201, 1987.

37. Woo E, Chan YF, Lam K, Lok ASF, Yu YL, Huang CY. Apoplectic intracerebral

hemorrhage: an unusual complication of cerebral radiation necrosis. Pathology 19:95-8,

1987.

38. Hui WM, Lam SK, Chau PY, Ho J, Lau WY, Poon KP, Lai CL, Lok ASF, Lui IOL, Ng

MMT. Pathogenetic role of campylobacter pyloridis in gastric ulcer. J Gastroenterol

Hepatol 2:309-16, 1987.


39. Lok ASF, Lai CL, Wu PC, Wong VCW, Yeoh EK, Lin HJ. Hepatitis B Virus Infection

in Chinese Families in Hong Kong. Am J Epidemiol 126:492-9. 1987.

40. Lai CL, Lok ASF, Lin HJ, Wu PC, Yeoh EK, Yeung CY. The effect of recombinant

alpha2-interferon in Chinese HBsAg carrier children: a prospective controlled trial.

Lancet 2:877-80, 1987.

41. Lai CL, Gregory PB, Wu PC, Lok ASF, Wong KP, Ng MMT. Hepatocellular carcinoma

in Chinese males and females: possible causes for the male predominance. Cancer

60:1107-11, 1987.

42. Lok ASF, Lai CL, Wu PC. A randomized, controlled trial of recombinant alpha-2

interferon in Chinese patients with chronic hepatitis B virus infection: an interim report.

In Viral Hepatitis and Liver Disease, ed. AJ Zuckerman, Alan R Liss Inc., New York pp

848-9, 1988.

43. Lai CL, Lok ASF, Lin HJ, Wu PC, Yeoh EK and Yeung CY. Effect of recombinant

alpha 2-interferon in Chinese Hepatitis B Surface Antigen Carrier Children: A

prospective, controlled trial. In Viral Hepatitis and Liver Disease ed. AJ Zuckerman,

Alan R Liss Inc., New York pp 850.

44. Lok ASF, Lai CL. Factors determining the development of hepatocellular carcinoma

(HCC) in hepatitis B surface antigen carriers: a comparison between families with

clusters and solitary cases of HCC. Cancer 61:1287-91, 1988.

45. Lok ASF, Lai CL, Wu PC. Prevalence of isolated antibody to hepatitis B core antigen in

an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination

programs. Hepatology 8:766-70, 1988.

46. Lai CL, Wu PC, Chan GCB, Lok ASF, Lin HJ. Doxorubicin vs no antitumor therapy in

inoperable hepatocellular carcinoma: a prospective, randomized trial. Cancer 62:479-83,

1988.

47. Lok ASF, Ng IOL. Prochlorperazine induced chronic cholestasis. J Hepatol 6:369-373,

1988.

48. Hui WM, Lam SK, Chau PY, Ho J, Lui I, Lai CL, Lok ASF, Ng MMT. Persistence of

Campylobacter pyloridis despite healing of duodenal ulcer and improvement of

accompanying duodenitis and gastritis. Dig Dis Sci 32:1255-60, 1987.


49. Lok ASF, Lai CL, Wu PC. A longitudinal follow-up of asymptomatic hepatitis B surface

antigen positive Chinese children. Hepatology 8:1130-3, 1988.

50. Lok ASF, Lai CL, Wu PC, Leung EKY. Long-term follow-up in a randomized,

controlled trial of recombinant alpha-2 interferon in Chinese patients with chronic

hepatitis B infection. Lancet 2:298-302, 1988.

51. Lok ASF, Lai CL. Alpha-fetoprotein monitoring in Chinese patients with chronic

hepatitis B infection: role in the early detection of hepatocellular carcinoma. Hepatology

9:110-5, 1989.

52. Chung HT, Lai CL, Wu PC and Lok ASF. Synergism of chronic alcoholism and hepatitis

B infection in liver disease. J Gastroenterol Hepatol 4:11-6, 1988.

53. Lok ASF, Lai CL, Wu PC. Response to hepatitis B vaccine in subjects positive for anti

HBc. In Asian symposium on strategies for large scale hepatitis B immunization, ed el

Gouli, Science Press (Hong Kong) pp 141-6, 1988.

54. Branicki FJ, Boey J, Fok PJ, Pritchett CJ, Fan ST, Lai ECS, Mok FPT, Wong WS, Lam

SK, Hui WM, Ng MMT, Lok ASF, Lam DKH, Tang APK, Coleman SY, Wong J.

Bleeding gastric ulcer: a prospective evaluation of rebleeding and mortality. Aust and N

Zealand J Surg 59:551-62, 1988.

55. Hui WM, Lam SK, Ho J, Ng I, Lam WY, Branicki FJ, Lai CL, Lok ASF, Ng MMT, Fok

PJ, Poon GP, Choi TK. The effect of sucralfate and cimetidine on duodenal ulcer

associated antral gastritis and Campylobacter pylori. Am J Med 86: (Suppl 6A) : 60-5,

1989.

56. Lau JYN, Lai CL, Lin HJ, Lok ASF, Liang RHS, Wu PC, Chan TK, Todd D. Fatal

reactivation of chronic hepatitis B virus infection following chemotherapy withdrawal in

lymphoma patients. Quart J Med 73:911-7, 1989.

57. Lok ASF, Lai CL. Acute exacerbation in Chinese patients with chronic hepatitis B virus

infection: incidence, etiology and predisposing factors. J Hepatol 10:29-34, 1990.

58. Wong KF, Yuen RWS, Lok ASF, Chan TK. Granulocytic sarcoma presenting as

bleeding gastric polyp. Pathology 21:63-4, 1989.

59. Lai CL, Wu PC, Lok ASF, Lin HJ, Ngan H, Lau JYN, Chung HT, Ng MMT, Yeoh EK,


Arnold M. Recombinant alpha2 interferon is superior to doxorubicin for inoperable

hepatocellular carcinoma: a prospective, randomized trial. Br J Cancer 60:928-33, 1989.

PMC2247256

60. Hui WM, Lam SK, Lau WY, Branicki FJ, Lok ASF, Ng MMT, Lai CL, Poon GP.

Omeprazole and ranitidine in duodenal ulcer healing and subsequent relapse: a

randomized, double-blind study with weekly endoscopic assessment. J Gastroenterol

Hepatol 4 (Suppl 2):35-44, 1989.

61. Lam SK, Hui WM, Ng MMT, Lok ASF, Lai CL, Branicki FJ, Lau WY, Poon GP.

Reducing meal-stimulated acid secretion achieves faster healing of duodenal ulcer than

reducing nocturnal acid secretion. Dig Dis Sci 34:1494-500, 1989.

62. Branicki FJ, Boey J, Fok PJ, Pritchett CJ, Fan ST, Lai ECS, Mok FPT, Wong WS, Lam

SK, Hui WM, Ng MMT, Lok ASF, Lam DKH, Tse MCK, Tang APK, Wong J. Bleeding

duodenal ulcer: a prospective evaluation of risk factors for rebleeding and death. Ann

Surg 211:411-8, 1990.

63. Lai ECS, Ng IOL, Ng MMT, Lok ASF, Tam PC, Fan ST, Choi TK, Wong J. Long-term

results of resection for large hepatocellular carcinoma: a multivariate analysis of clinico-

pathological features. Hepatology 11:815-8, 1990.

64. Lok ASF, Lai CL, Leung EKY. Interferon antibodies may negate the antiviral effects of

recombinant alpha-interferon treatment in patients with chronic hepatitis B virus

infection. Hepatology 12:1266-70, 1990.

65. Lok ASF, Ma OCK. Hepatitis B virus replication in Chinese patients with hepatocellular

carcinoma. Hepatology 12:582-8, 1990.

66. Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TK, Todd D. Reactivation of

hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroenterol

100:182-8, 1991.

67. Lok ASF, Lai CL. Incidence, neutralizing activity and clinical significance of interferon

antibodies in chronic hepatitis B patients receiving recombinant alpha interferons. In

Viral Hepatitis and Liver Disease, ed. Hollinger FB, Lemon SM, Margolis HS, Williams

and Wilkins, Baltimore, 643-5, 1991.

68. Liang RHS, Lok ASF, Lai CL, Chan TK, Todd D, Chiu EKW. Hepatitis B infection in

patients with lymphomas. Hemat Oncol 8:261-70, 1990.


69. Lai CL, Lau JYN, Lin HJ, Lok ASF, Wu PC, Chung HT, Wong LSK, Leung MP, Yeung

CY. Effect of recombinant alpha2 interferon with or without prednisone in Chinese

HBsAg carrier children: a prospective, double-blind, controlled trial. Quart J Med

286:155-63, 1991.

70. Lok ASF, Ma OCK, Lau JYN. Alpha-interferon therapy in patients with chronic hepatitis

B virus infection: effects on hepatitis B virus deoxyribonucleic acid in the liver.

Gastroenterol 100:756-61, 1991.

71. Lok ASF, Lai CL, Chung HT, Lau JYN, Leung EKY, Wong LSK. Morbidity and

mortality from chronic hepatitis B virus infection in family members of patients with

malignant and non-malignant hepatitis B virus related chronic liver diseases. Hepatology

13:834-7, 1991.

72. Hui WM, Lam SK, Ho J, Lai CL, Lok ASF, Ng MMT, Lau WY, Branicki FJ. The effect

of omeprazole on duodenal ulcer-associated antral gastritis and helicobacter pylori. Dig

Dis Sci 36:577-82, 1991.

73. Chin KP, Lok ASF, Wong LSK, Lai CL, Wu PC. Current seroepidemiology of hepatitis

A in Hong Kong. J Med Virol 34:191-3, 1991.

74. Lau JYN, Lai CL, Wu PC, Chung HT, Lok ASF, Lin HJ. Randomized, controlled trial of

recombinant interferon-gamma in chronic hepatitis B virus infection. J Med Virol

34:184-7, 1991.

75. Chan TM, Lok ASF, Cheng IKP. Hepatitis C in renal transplant recipients.

Transplantation 52:810-3, 1991.

76. Hui WM, Ng MMT, Lok ASF, Lai CL, Lau YN, Lam SK. A randomized, prospective

study of the efficacy of laser, heater probe and bipolar electrocoagulation in acute

bleeding ulcer. Gastrointest Endosc 37:299-304, 1991.

77. Chan TM, Lok ASF, Cheng IKP. Hepatitis C infection among dialysis patients: a

comparison between patients on maintenance haemodialysis and continuous ambulatory

peritoneal dialysis. Nephrol Dial Transp 6:944-7, 1991.

78. Lok ASF, Ma OCK, Chan TM, Lai CL, Chung HT, Ng CPL, Lam JSC. Over estimation

of the prevalence of antibody to hepatitis C virus in retrospective studies on stored sera.

Hepatology 14:756-62, 1991.


79. Lok ASF, Wong, A, Sporton S, Lai CL, Liu V, Chung HT. Hepatitis D virus

superinfection remains a rare occurrence in non-drug abusers in Hong Kong. J Hepatol

14:332-4, 1992.

80. Thomas HC, Dusheiko GM, Farrell G, Cooksley WEF, Lok ASF, Perez V, Tanno H,

Carreno V, Ryff JC. Comparative study of three doses of interferon alpha-2a in chronic

active hepatitis B ed Hollinger FB, Lemon SM, Margolis HS, Williams and Wilkins,

Baltimore, 641-2, 1991.

81. Carman WF, Ferrao M, Lok ASF, Ma OCK, Lai CL, Thomas HC. Pre-core sequence

variation in Chinese isolates of hepatitis B virus: relationship to HBe status and activity

of liver disease. J Infect Dis 165:127-33, 1992.

82. Chan PCK, Lok ASF, Cheng IKP, Chan MK. The impact of donor and recipient hepatitis

B surface antigen status on liver disease and survival in renal transplant recipients.

Transplantation 53:128-31, 1992.

83. Hui WM, Lam SK, Lok ASF, Ng MMT, Lai CL. Maintenance therapy for duodenal

ulcer: A randomized controlled comparison of seven forms of treatment. Am J Med

92:265-74, 1992.

84. Lok ASF, Wu PC, Lai CL, Lau JYN, Leung EKY, Wong LSK, Ma OCK, Lauder IJ, Ng

CPL, Chung HT. A controlled trial of interferon with or without prednisone priming for

chronic hepatitis B. Gastroenterol 102:2091-7, 1992.

85. Lok ASF, Cheung R, Chan R, Liu V. Hepatitis C viremia in patients with hepatitis C

virus infection. Hepatology 15:1007-12, 1992.

86. Wu PC, Lok ASF, Lau JYN, Lauder IJ, Lai CL. Histologic changes in Chinese patients

with chronic hepatitis B virus infection following interferon - alpha therapy. Am J Clin

Pathol 98: 402-7, 1992.

87. Wong SN, Yu ECL, Lok ASF, Chan KW, Lau YL. Interferon treatment for hepatitis B

associated membranous glomerulonephritis in two Chinese children. Paed Nephrol

6:417-20, 1992.

88. Cheung R, Lok ASF. Correlation between HCV viremia and spontaneous or interferon

induced remissions in chronic hepatitis C. Proc 3rd Int'l Symposium on HCV,

Strasbourg, 1991.


89. Chung HT, Lok ASF, Lai CL. Re-evaluation of interferon treatment of chronic hepatitis

B using polymerase chain reaction. J Hepatol 17:208-14, 1993.

90. Chan TM, Lok ASF, Cheng IKP, Chan RT. Prevalence of hepatitis C virus (HCV)

infection in hemodialysis patients: a longitudinal study comparing the results of HCV

RNA and anti-HCV assays. Hepatology 17:5-8, 1993.

91. Cheng IKP, Chan DTM, Lok ASF. Hepatitis C infection among renal transplant

recipients: a comparative study using first and second generation anti-HCV EIA and HCV

detection by nested PCR. Trans Proc 25:1460-2, 1993.

92. Lok ASF, Kwan WK, Moeckli R, Yarbough PO, Chan RT, Reyes GR, Lai CL, Chung

HT, Lai TST. A seroepidemiological survey of hepatitis E in Hong Kong using

recombinant based enzyme immunoassays. Lancet 2:1205-9, 1992.

93. Chan TM, Lok ASF, Cheng IKP, Chan RT. A prospective study on hepatitis C virus

infection among renal transplant recipients. Gastroenterol 104:862-8, 1993.

94. Terris B, Machio A, Mattei MG, Fagan E, Lok A, Tiollais P, Dejean A. Abnormal

expression of hepatitis B virus sequences integrated in human hepatocellular carcinomas.

Gastroenterologie Clinique Biologique 16:511-7, 1992.

95. Hui WM, Shiu LP, Lok AS, Lam SK. Life events and daily hassles in duodenal ulcer

disease. A prospective study of patients with active disease and in remission. Digestion

52:165-72, 1992.

96. Cheung RC, Chan RT, Lok ASF. Longitudinal study of hepatitis C viremia in chronic

hepatitis C. J Med Virol 41:338-42, 1993.

97. Chan TM, Lok ASF, Cheng IKP, Ng IOL, Chan KW. Chronic hepatitis C after renal

transplantation: treatment with alpha interferon. Transplantation 56:1095-8, 1993.

98. Lok ASF, Chien D, Choo QL, Chan TM, Chiu EKW, Cheng IKP, Houghton M, Kuo G.

Antibody response to core, envelope and non-structural hepatitis C virus antigens:

comparison between immunocompetent and immunosuppressed patients. Hepatology

18:497-502, 1993.

99. Chung HT, Lee JSK, Lok ASF. Prevention of post-transfusion hepatitis B and C by

screening for antibody to hepatitis C virus and antibody to hepatitis B core antigen.


Hepatology 18:1045-9, 1993.

100. Lok ASF, Chung HT, Liu VWS, Ma OCK. Long-term follow-up of chronic hepatitis B

patients treated with alpha interferon. Gastroenterol 105:1833-8, 1993.

101. Lok ASF, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus

serve to enhance the stability of the secondary structure of the pregenome encapsidation

signal. Proc Natl Acad Sci USA 91:4077-81, 1994. PMC43726

102. Akarca US, Greene S, Lok ASF. Detection of pre-core hepatitis B virus mutants in

asymptomatic hepatitis B surface antigen positive family members. Hepatology 19:1366-

70, 1994.

103. Crowe JS, Gewert DR, Barber KA, Lewis AP, Sims MJ, Davies SL, Salom CL, Wood J,

Thomas HC, Thursz M, Lok AS. Interferon alpha-2 genotype analysis of Chinese chronic

hepatitis B patients undergoing recombinant interferon-alpha 2a therapy. J Infect Dis

169:875-8, 1994.

104. Lok ASF, Akarca US, Greene S. Predictive value of pre-core hepatitis B virus mutations

in spontaneous and interferon induced hepatitis B e antigen clearance. Hepatology 21:19-

24, 1995.

105. Chan TM, Wu PC, Lau JYN, Lai CL, Lok ASF, Cheng IKP. Clinicopathologic features

of hepatitis C virus infection in renal allograft recipients. Transplantation 58:996-1000,

1994.

106. Thomas HC, Lok ASF, Carreno V, Farrell G, Tanno H, Perez V, Dusheiko GM, Cooksley

G, Ryff JC and the International Hepatitis Trial Group. Comparative Study of three doses

of interferon -2a in chronic active hepatitis B. J Viral Hep 1:139-148, 1994.

107. Chung HT, Lai CL, Lok ASF. Pathogenic role of hepatitis B virus in hepatitis B surface

antigen negative decompensated cirrhosis. Hepatology 22:25-29, 1995.

108. Akarca US and Lok ASF. Naturally occurring hepatitis B virus core gene mutations.

Hepatology 22:50-60,1995.

109. Akarca US and Lok ASF. Naturally occurring core gene defective hepatitis B viruses. J

Gen Virol 76:1821-6, 1995.

110. Ghany MG, Leissinger C. Lagier R, Sanchez-Pescador R, Lok ASF. Effect of human


immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs. Dig Dis

Sci 41:1265-72, 1996.

111. Zhang YY, Lok ASF, Chan DTM, Widell A. Greater diversity of hepatitis C virus

genotypes found in Hong Kong than in mainland China. J. Clin Microbiol 33:2931-4,

1995. PMC228609

112. Bozkaya H, Ayola B, Lok ASF. High rate of mutations in the hepatitis B core gene

during the immune clearance phase of chronic hepatitis B virus infection. Hepatology

24:32-37, 1996.

113. Haque S, Chandra B, Gerber MA, Lok ASF. Iron overload in patients with chronic

hepatitis C: a clinicopathologic study. Human Pathol 27:1277-81, 1996.

114. Ghany MG, Chan TM, Sanchez-Pescador R, Urdea M, Lok ASF. Correlation between

serum HCV RNA and aminotransferase levels in patients with chronic HCV infection.

Dig Dis Sci 41:2213-8, 1996.

115. Bozkaya H, Akarca US, Ayola B, Lok ASF. High degree of conservation in the hepatitis

B virus core gene during the immune tolerant phase in perinatally acquired chronic

hepatitis B virus infection. J Hepatol 26:508-516, 1997.

116. Lau GKK, Lok ASF, Liang RHS, Lai CL, Chiu EKW, Lau YL, Lam SK. Clearance of

HBsAg after bone marrow transplantation: role of adoptive immunity transfer.

Hepatology 25:1497-1501, 1997

117. Shehab TM, Kaminski MS, Lok ASF. Acute liver failure due to hepatic involvement by

hematologic malignancy. Dig Dis Sci 42:1400-5, 1997.

118. Chan TM, Wu PC, Lau JYN, Lok ASF, Lai CL, Cheng IKP. Interferon treatment for

hepatitis C virus infection in patients on hemodialysis. Nephrol Dial Transplant 12:1414-

9, 1997.

119. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok ASF. Hepatitis

B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B

immune globulin prophylaxis. Hepatology 27:213-222, 1998.

120. Lok ASF, Ghany MG, Watson G, Ayola B. Predictive value of aminotransferase and

hepatitis B virus DNA levels in response to interferon therapy for chronic hepatitis B. J

Viral Hep 5:171-178, 1998.


121. Chan TM, Lau JYN, Wu PC, Lai CL, Lok ASF, Cheng IKP. Hepatitis C virus genotypes

in patients on renal replacement therapy. Nephrol Dial Transplant 13:731-4, 1998.

122. Chan HLY, Hussain M, Lok ASF. Different hepatitis B virus genotypes are associated

with different mutations in the core promoter and precore regions during HBeAg

seroconversion. Hepatology 29:976-984, 1999.

123. Shehab TM, Sonnad SS, Jefferies M, Gunaratnam N, Lok ASF. Current practice patterns

of primary care physicians in the management of patients with hepatitis C. Hepatology

30: 794-800, 1999.

124. Chan HLY, Leung NWY, Hussain M, Wong ML, Lok ASF. Hepatitis B e antigen

negative chronic hepatitis B in Hong Kong. Hepatology 31:763-768, 2000.

125. Lok ASF, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, Jovine E, Benardi

M, Andreone P. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e

antigen negative patients receiving lamivudine therapy. Hepatology 32:1145-1153, 2000.

126. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF

and the HEP DART International Committee. Nomenclature for antiviral resistant human

hepatitis B virus mutations in the polymerase region. Hepatology 33:751-757, 2001.

127. Fontana RJ, Moyer CA, Sonnad SS, Lok ASF, Sneed-Pee N, Walsh J, Klein S, Webster

S. Co-morbidities and quality of life in patients with interferon refractory chronic

hepatitis C. Am J Gastroenterol 96:170-178, 2001.

128. Teo EK, Ostapowicz G, Hussain M, Lee WM. Fontana RJ, Lok ASF. Hepatitis B

infection in patients with acute liver failure in the United States. Hepatology 33:972-976,

2001.

129. Shehab, TM, Sonnad SS, Lok ASF. Management of hepatitis C patients by primary care

physicians in the United States: results of a national survey. J Viral Hepatitis 8:377-383,

2001.

130. Teo EK, Han SH, Terrault, N. Luketic V, Jensen D, Keeffe EB, Lok ASF and the HBV-

OLT Study Group. Liver transplantation in patients with hepatitis B virus infection:

outcome in Asians versus Whites. Hepatology 34:126-132, 2001.

131. Funk ML, Rosenberg DM, Lok AS. Worldwide epidemiology of HBeAg-negative


chronic hepatitis B (e-CHB) and associated precore and core promoter variants. J Viral

Hepatitis 9:52-61,2002.

132. Hussain KB, Fontana RJ, Moyer CA, Su GL, Sneed-Pee N, Lok ASF. Co-morbid illness

is an important determinant of health related quality of life in patients with chronic

hepatitis C. Am J Gastroenterol 96:2737-2744, 2001.

133. Fontana RJ, Hussain KB, Schwartz S, Moyer C, Su G, Lok ASF. Emotional distress in

hepatitis C patients not receiving antiviral therapy. J Hepatol 36:401-7, 2002.

134. Chu CJ, Fontana RJ, Moore C, Armstrong DR, Punch JD, Su GL, Magee JC, Merion

RM, Lok ASF. Outcome of liver transplantation for hepatitis B: report of a single center's

experience. Liver Transpl 7:724-731,2001.

135. Chu CJ, Hussain M, Lok ASF. Hepatitis B virus genotype B is associated with earlier

HBeAg seroconversion compared to hepatitis B virus genotype C. Gastroenterol

122:1756-1762, 2002.

136. Fontana RJ, Schwartz SM, Gebremariam A, Lok ASF, Moyer CA. Emotional distress

during interferon 2b and ribavirin treatment of chronic hepatitis C. Psychosomatics

43:378-385, 2002.

137. Fontana RJ, Keeffe EB, Carey W, Fried M, Reddy R, Kowdley, Soldevila-Pico C,

McClure LA, Lok ASF for the NIH HBV-OLT study group. Effect of Lamivudine

treatment on survival of 309 North America patients awaiting liver transplantation for

chronic hepatitis B. Liver Transpl 8:433-439, 2002.

138. Fontana RJ, Walsh J, Moyer CA, Lok AS, Webster S, Klein S. High-dose interferon alfa-

2b and ribavirin in patients previously treated with interferon: results of a prospective,

randomized, controlled trial. J Clin Gastroenterol 34(2):177-82, 2002

139. Shehab TM, Orrego M, Chunduri R, Lok ASF. Identification and management of

Hepatitis C patients in primary care clinics. Am J Gastroenterol 98:639-644, 2003.

140. Lok ASF, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, Maertens G,

Hulstaert F, DeVreese K, Sablon E. Monitoring drug resistance in chronic Hepatitis B

patients during Lamivudine therapy: performance evaluation of INNO-LIPA HBV D R. J

Clin Microbiol 40:3729-34, 2002. PMC130856.


141. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick D, Lok AS. NAFLD may be a

common underlying liver disease in patients with hepatocellular carcinoma in the United

States. Hepatology 36:1349-54, 2002.

142. Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different

stages of chronic hepatitis B infection. Hepatology 36:1408-15, 2002.

143. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with higher rate of

response to interferon therapy in Chinese patients with HBeAg positive chronic hepatitis

than genotype C. Hepatology 36:1425-30, 2002.

144. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Des-

gamma carboxyprothrombin can differentiate hepatocellular carcinoma from

nonmalignant chronic liver disease in American patients. Hepatology 37:1114-1121,

2003.

145. Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, Carey W, Brown Jr

RS, Luketic VA, Terrault N, Lok AS. HBV genotypes in the United States: results of a

nationwide study. Gastroenterol 125:444-451, 2003.

146. Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, Carey W, Brown Jr

RS, Luketic VA, Terrault N, Lok AS. Prevalence of HBV precore/core promoter variants

in the United States. Hepatology 38:619-628, 2003.

147. Hussain M, Chu CJ, Sablon E, Lok ASF. Rapid and sensitive assays for the determination

of HBV genotypes and the detection of HBV precore and core promoter variants. J Clin

Microbiol 41:3699-3705, 2003. PMC179815.

148. Wai C, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok

AS. A simple non-invasive index can predict both significant fibrosis and cirrhosis in

patients with chronic hepatitis C. Hepatology 38:518-526, 2003.

149. Moyer CA, Fontana RJ, Hussain K, Lok ASF, Schwartz S. The role of

optimism/pessimism in HRQOL in chronic hepatitis C patients. J Clin Psychol in Med

Settings. 10:41-49, 2003.

150. Lok ASF, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ,

Little NR, Griffiths DA, Gardner SD, Castiglia M. Long-term safety of lamivudine

treatment in patients with chronic hepatitis B. Gastroenterol 125:1714-1722, 2003.


151. DiBisceglie AM, Lyra AC, Schwarz M, Reddy RK, Martin P, Gores G, Lok AS, Hussain

KB, Gish R, van Thiel DH, Younossi Z, Tong M, Hassanein T, Balart L, Fleckenstein J,

Flamm S, Blei A, Befeler AS, and the Liver Cancer Network. Hepatitis C related

hepatocellular carcinoma in the United States: influence of ethnic status. Am J

Gastroenterol 98:2060-3, 2003.

152. Shehab TM, Fontana RJ, Oberhelman K, Marrero JA, Su GL, Lok ASF. Effectiveness of

interferon-2b and ribavirin therapy in treatment naïve chronic hepatitis C patients in an

academic clinical practice. Clin Gastro and Hepatol 2: 425-431, 2004.

153. Fung SK, Wong F, Hussain M, Lok ASF. Sustained response after a 2-year course of

lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat

11:432-8, 2004.

154. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson ET, Lok

AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD,

Everhart JE and the HALT-C Trial Group. Peginterferon alfa-2a and ribavirin in patients

with chronic hepatitis C who have failed prior treatment. Gastroenterol 126:1015-1023,

2004.

155. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, Everson GT,

DiBisceglie AM, Morgan TR, Ghany MG, Morishima C, Wright EC, Everhart JE.

Evolution of the HALT-C Trial: Pegylated Interferon as Maintenance Therapy for

Chronic Hepatitis C in Previous Interferon Nonresponders. Controlled Clinical Trials

25:472-492, 2004.

156. Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, Tobacco and

Obesity Are Synergistic Risk Factors for Hepatocellular Carcinoma. J Hepatol 42:218-

224, 2005.

157. Wai CT, Fontana RJ, Polson J, Hussain M, Shakil AO, Han SH, Davern TJ, Lee WM,

Lok ASF and the US Acute Liver Failure Study Group. Clinical Outcome and virological

characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hepat

12:192-8, 2005.

158. Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok AS. Improving the

prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing

liver mass. Liver Transpl 11:281-289, 2005.

159. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS.


Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American

cohort. Hepatology 41:707-716, 2005.

160. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Herbert L.

Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok ASF, Lee WM, Morgan TR,

Ghany MG, Gretch DR and the HALT-C Trial Group. Serum alpha-fetoprotein levels in

patients with advanced hepatitis C: results from the HALT-C trial. J Hepatol 43:434-441,

2005.

161. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, Emick D, Lok

AS, Conjeevaram HS. One-year intense nutritional counseling results in histological

improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J

Gastroenterol 100:1072-1081, 2005.

162. Lok ASF, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE,

Lindsay KL, Bonkovsky HL, DiBisceglie AM, Lee WM, Morgan TR, Dienstag JL,

Morishima C and the HALT-C Trial Group. Predicting cirrhosis in patients with hepatitis

C based on standard laboratory tests: results in the HALT-C cohort. Hepatology 42:282-

292, 2005.

163. Fung SK, Andreone P, Han SH, K. Reddy R, Regev A, Keeffe EB, Hussain M, Cursaro

C, Richtmyer P, Marrero JA, Lok ASF. Adefovir-resistant Hepatitis B can be Associated

with Viral Rebound and Hepatic Decompensation. J Hepatol 43:937-943, 2005.

164. Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale MA,

Lok AS , D’Amelio A and Timothy M. Block TM. GP73, a resident Golgi glycoprotein,

is a novel serum marker for Hepatocellular Carcinoma. J Hepatol 43:1007-12, 2005.

165. Fontana RJ, Bieliauskas LA, Back-Madruga C, Lindsay KL, Kronfol Z, Lok AS, Latha

Padmanabhan L, and the HALT-C Trial Group. Cognitive function in Hepatitis C

patients with advanced fibrosis: Results from the HALT-C trial. J Hepatol 43:614-622,

2005. PMC3772520

166. McGuire BM, Bonkovsky HL, Carithers RL, Chung RT, Goldstein LI, Lake JR, Lok AS,

Potter CJ, Rand E, Voigt MD, Davis PR, Bloomer JR. Liver Transplantation for

Erythropoietic Protoporphyria Liver Disease. Liver Transpl 11:1590-6, 2005.

167. Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero JA, Oberhelman K, Hussain

M, Lok AS. Virologic Response and Resistance to Adefovir in Patients with Chronic

Hepatitis B. J Hepatol; 44:283-290, 2006.

168. Bielauskas LA, Back-Madruga C, Lindsay KL, Snow KK, Kronfol Z, Lok AS,

Padmanabhan L, Fontana RJ and the HALT-C Trial Group. Clinical relevance of

cognitive scores in hepatitis C patients with advanced fibrosis. J Clin Exp Neuropsychol


28:1346-1361, 2006.

169. Dickson RC, Terrault NA, Ishitani M, Reddy KR, Sheiner P, Luketic V, Soldevila-Pico

C, Fried M, Jensen D, Brown RS Jr, Horwith G, Brundage R, Lok A. Protective antibody

levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined

with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease.

Liver Transpl; 29:124-133, 2006. PMC1393162

170. Hussain M, Fung S, Libbrecht E, Sablon E, Cursaro C, Andreone P, Lok ASF. Sensitive

line probe assay that simultaneously detects mutations conveying resistance to lamivudine

and adefovir. J Clin Microbiol; 44: 1094-7, 2006.

171. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber

R, Zink RC, Cross A, Colonno R, Fernandes L for the AI463027 BEHoLD Study Group.

A randomized, double-blind comparison of entecavir to lamivudine for treatment of

HBeAg-negative chronic hepatitis B in nucleoside-naïve patients. N Engl J Med;

354:1011-1020, 2006.

172. Chang TT, Gish RG, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhy

J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D for the Entecavir BEHoLD

AI463022 Study Group. A randomized, double-blind comparison of entecavir to

lamivudine for treatment of HBeAg-positive chronic hepatitis B in nucleoside-naïve

patients. N Engl J Med; 354:1001-1010, 2006.

173. Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, Lindsay

KL, Lok ASF, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG,

Gretch DR and the HALT-C Trial Group. HCV RNA detection by TMA during the

hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology;

44:360-7, 2006.

174. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok ASF. Evolution of multi-drug

resistant hepatitis B virus during sequential therapy: implications on rescue therapy.

Hepatology; 44: 703-712, 2006.

175. Fung SK, Wong FSH, Wong DKH, Hussain MT, Lok ASF. Hepatitis B virus genotypes,

precore and core promoter variants among predominantly Asian patients with chronic

HBV infection in a Canadian center. Liver Int 26:796-804, 2006.

176. Wong SN, Reddy KR, Keeffe EB, Han SH, Gaglio PJ, Perrillo RP, Tran TT, Pruett TL,

Lok ASF and the NIH HBV-OLT Study Group. Comparison of clinical outcomes in


chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma.

Liver Transpl 13:334-342, 2007.

177. Lok ASF, Everhart JE, Chung RT, Padmanabhan L, Greenson JK, Shiffman ML, Everson

GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM. Lee WT, Morgan TR, Ghany MG,

Morishima C and the HALT-C Trial Group. Hepatic Steatosis in Hepatitis C: Comparison

of Diabetic and non-diabetic Patients in the Hepatitis C Antiviral Long-Term Treatment

against Cirrhosis Trial. Clin Gastro Hepatol 5:245-254, 2007.

178. Terrault NA, Shiffman ML, Lok ASF, Saab S, Tong L, Brown RS, Everson GT, Reddy R,

Fair JH, Kulik LM, Pruett TL, Seeff LB and the A2ALL Study Group. Outcomes in

hepatitis C virus infected recipients of living donor versus deceased donor liver

transplantation. Liver Transpl; 13:122-9, 2007. PMC3155862

179. Shiffman ML, Ghany MG, Morgan TR, WrightEC, Everson GT, Lindsay KL, Lok ASF,

Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Gretch DR, and the HALT-C

Trial Group. Impact of reducing peginterferon alfa-2a and ribavirin dose on virologic

response in patients with chronic hepatitis C. Gastroenterology 132:103-12, 2007.

180. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn

JA, Lok ASF, Di Bisceglie AM, Lee WM, Dienstag JL,

Ghany MG, Morishima C, and

the HALT-C Trial Group. Impact of disease severity on outcome of antiviral therapy for

chronic hepatitis C: lessons from the HALT-C Trial. Hepatology 44:1675-1684, 2006.

181. Wong SN, Chu CJ, Wai CT, Howell T, Moore C, Fontana RJ and Lok ASF. HBV

recurrence is infrequent after withdrawal of long-term hepatitis B immune globulin

(HBIG) in patients receiving maintenance nucleos(t)ide analogue (NA) therapy. Liver

Transpl 13;374-381, 2007.

182. Volk ML, Marrero JA, Lok AS, Ubel PA. Who decides? Living donor liver

transplantation for advanced hepatocellular carcinoma. Transplantation 82: 1136-9, 2006.

183. Liu Y, Hussain M, Wong S, Fung SK, Yim HJ, Lok AS. A genotype-independent real-

time PCR assay for quantification of hepatitis B virus DNA. J Clin Microbiol 45:553-8,

2007. PMC1829020

184. Fontana RJ, Bieliauskas LA, Lindsay KL, Back-Madruga C, Wright EC, Snow KK, Lok

ASF, Kronfol Z, Latha Padmanabhan L and the HALT-C Trial Group. Cognitive

function does not worsen during peginterferon and ribavirin treatment of chronic hepatitis

C. Hepatology 45:1154-63, 2007.


185. Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, Askari F,

Sullivan P, and Lok AS. Sustained virologic response to therapy of recurrent hepatitis C

after liver transplantation is related to early virologic response and dose adherence. Liver

Transpl 13:1100-8, 2007.

186. Hussain M, Soldevila-Pico C, Emre S, Luketic V, Lok AS and the NIH HBV-OLT Study

Group. Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV

recurrence after liver transplant. Liver Transpl 13:1137-44, 2007.

187. Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA. Risk factors for hepatocellular

carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and

AFP-L3. Cancer Biomarkers 3:79-87, 2007.

188. Fisher RA, Kulik LM, Freise CF, Lok ASF, Shearon TH, Brown RS, Ghobrial RM, Fair

JH, Olthoff KM, Kam I, Berg CL and the A2ALL Study Group. Hepatocellular

carcinoma recurrence and death following living and diseased donor liver transplantation:

the A2ALL Study. Am J Transpl 7:1601-8, 2007. PMC3176596

189. Volk ML, Hernandez JC, Lok AS, Marrero JA. A modified Charlson Comorbidity Index

for predicting survival after liver transplantation. Liver Transpl 13:1515-1520, 2007.

190. Bieliauskas LA, Back-Madruga C, Lindsay KL, Wright EC, Kronfol Z, Lok AS, Fontana

RJ and the HALT-C Trial Group. Cognitive reserve and neuropsychological functioning

in patients infected with hepatitis C. J Int Neuropsychol Soc 18: 1-6, 2007.

191. Osborn MK, Han SH, Regev A, Bzowej NH, Ishitani MB, Tran TT, Lok ASF and the

NIH HBV-OLT Study Group. Outcomes of patients with hepatitis B who developed

antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol and

Hepatol 5:1454-1461, 2007. PMC2645788

192. Shetty K, Hussain M, Nei L, Reddy KR, Lok ASF. The prevalence and significance of

occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver

Transplantation 14: 534-540, 2008. PMID: 18324677

193. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Han KH, Chao YC, Lee SD,

Harris M, Yang J, Colonno R, Brett-Smith H. Entecavir therapy up to 96 weeks in

patients with HBeAg-positive chronic hepatitis B. Gastroenterology 133: 1437-1444,

2007.


194. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky H, Dienstag JL, Shiffman ML,

Lindsay KL, Lok ASF, DiBisceglie AM, Lee WM, Ghany MG and the HALT-C Trial

Group. Use of Herbal Products by Persons Enrolled in the Hepatitis C Antiviral Long-

Term Treatment against Cirrhosis (HALT-C) Trial. Hepatology 47: 605-12, 2008. PMID:

18157835

195. Tan J, Degertekin B, Wong SN, Hussain M, Oberhelman K, Lok ASF. Tenofovir

monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir

in the absence of adefovir-resistant mutations. J Hepatol 48: 391-8, 2008. PMID:

18199519

196. Lindsay KL, Morishima C, Wright EC, Dienstag JL, Shiffman ML, Everson GT, Lok AS,

Bonkovsky HL, Lee WM, Morgan TR, Ghany MG, and the HALT-C Trial Group.

Blunted cytopenias and weight loss: new correlates of virologic null response to re-

treatment of chronic hepatitis C. Clin Gastroenterol Hepatol 6: 234-41, 2008. PMID:

18237873

197. Campsen J, Blei AT, Emond JC, Everhart JE, Freise CE, Lok AS, Saab S, Wisniewski

KA, Trotter J, and the A2ALL Study Group. Outcomes of living donor liver

transplantation for acute liver failure: A2ALL study. Liver Transplantation 14:1273-80,

2008. PMC3732478

198. Morishima C, Morgan TR, Everhart JE, Wright EC, Apodaca MC, Gretch DR, Shiffman

ML, Verson GT, Lindsay KL, Lee WM, Lok ASF, Dienstag JL, Ghany MG, Curto TM

and the HALT-C Trial Group. Interpretation of positive TMA test results from PCR-

negative samples obtained after treatment of chronic hepatitis C. Hepatology; 48:1412-9,

2008. PMC2804270

199. Fontana RJ, Kronfol Z, Lindsay KL, Bieliauskas LA, Padmanabhan L, Back-Madruga C,

Lok ASF, Stoddard AM, and the HALT-C Trial Group. Changes in Mood States and

Biomarkers during Peginterferon and Ribavirin Treatment of Chronic Hepatitis C. Am J

Gastroenterol 103: 2766-75, 2008. PMC3712502

200. Gaglio P, Singh S, Degertekin, B, Ishitani M, Hussain M, Perrillo R, Lok ASF and the

NIH HBV-OLT Study Group. Impact of HBV genotype on pre- and post- liver

transplantation outcomes. Liver Transplantation 14: 1420-7, 2008. PMID: 18825703

201. Sharma P, Schaubel DE, Sima CS, Merion RM, Lok AS. Re-weighting the Model for

End-Stage Liver Disease Score Components. Gastroenterology 135:1575-81, 2008.

PMID: 18835388


202. DiBisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee

WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK,

Dienstag JL for the HALT-C Trial Group. Prolonged therapy of advanced chronic

hepatitis C with low dose peginterferon. NEJM 359: 2429-41, 2008. PMC2606037.

203. Volk ML, Lok ASF, Pelletier SJ, Ubel PA, Hayward RA. The impact of MELD

allocation policy on utilization of high risk organs for liver transplantation. Gastroenterol

135:1568-74, 2008. PMID: 19009713

204. Lok AS, Seeff LB, Morgan TR, Di Bisceglie AM, Sterling RK, Curto TM, Everson GT,

Lindsay KL,Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman

ZD, and the HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated

risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136: 138-148,

2009. PMC3749922

205. Friese CE, Gillespie BW, Koffron AJ, Lok ASF, Pruett TL, Emond JC, Fair JH, Olthoff

KM, Trotter JF, Ghobrial RM, Everhart JE and the A2ALL Study Group. Recipient

Morbidity after Living and Deceased Donor Liver Transplantation: Findings from the

A2ALL Retrospective Cohort Study. Am J Transpl 8:2569-79, 2008. PMC 3297482.

206. Volk ML, Lok AS, Ubel PA, Viajn S. Beyond Utilitarianism: a method for analyzing

competing ethical principles in a decision analysis of liver transplantation. Med Decis

Making 28: 763-772, 2008. PMID: 18725405

207. Degertekin B, Hussain M, Tan J, Oberhelman K, Lok AS. Sensitivity and accuracy of an

updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis

B antiviral resistance. J Hepatol 50: 42-8, 2009. PMID: 19019484

208. Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, Lok AS, Su GL

and the HALT-C Trial Group. Serum fibrosis marker levels decrease after successful

antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin

Gastroenterol Hepatol 7: 219-26, 2009. PMC3766729

209. Lok AS , Everhart JE

, Chung RT

, Kim H

, Everson GT, Hoefs JC, Greenson JK

, Sterling

RK, Lindsay KL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Ghany MG, Morishima C,

and the HALT-C Trial Group. Evolution of hepatic steatosis in patients with advanced

hepatitis C: results from the HALT-C Trial. Hepatology 49: 1828-37, 2009.

PMC2692566.


210. Bzowej N, Han S, Degertekin B, Keeffe EB, Emre S, Brown R, Reddy R, Lok AS, and

the NIH HBV OLT Study Group. Liver Transplantation Outcomes among Caucasians,

Asian Americans and African Americans with Hepatitis B. Liver Transpl 28: 1010-20,

2009. PMID: 19718627

211. Ito K, Kim KH, Lok AS, Tong S. Characterization of genotype specific carboxyl terminal

cleavage sites of hepatitis B virus e antigen precursor and identification of furin as the

candidate enzyme. J Virol; 83: 3507-17, 2009. PMC2663268

212. Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL, Chung RT, Bonkovsky H,

Ghany MG and the HALT-C Trial Group. Weight Related Effects on Disease Progression

in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis Trial. Gastroenterol

137: 549-57, 2009. PMCID: 3148692

213. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois

D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S,

Schwartz M. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound

alfafetoprotein in early hepatocellular carcinoma. Gastroenterol 137: 110-8, 2009.

PMC2704256

214. Sharma P, Welch K, Eikstadt R, Marrero JA, Fontana RJ, Lok AS. Renal Outcomes after

Liver Transplantation in the MELD Era. Liver Transpl 28:1142-8, 2009. PMID:19718633

215. Orman ES and Lok AS. Outcomes of Patients with Chest Tube Insertion for Hepatic

Hydrothorax. Hepatol Int 3: 582-6, 2009. PMC2790584

216. Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM,

Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC11

MD, Dienstag JL, Morishima C,

Abnet CC, Sinha R, and the HALT-C Trial Group. Coffee Intake Is Associated with

Lower Rates of Liver Disease Progression in Chronic Hepatitis C. Hepatology 50: 1360-

9, 2009. PMC2783828

217. Pelletier SJ, Fu S, Thyagarajan V, Romero-Marrero C, Batheja MJ, Punch JD, Magee JC,

Lok AS, Fontana RJ, Marrero JA. An intention-to-treat analysis of liver transplantation

for hepatocellular carcinoma using organ procurement transplant network data. Liver

Transpl 29: 859-868, 2009. PMID: 19642139

218. Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC,

Naishadham D, Everson GT, Lok AS, DiBisceglie AM, Bonkovsky HL, Ghany MG and

the HALT-C Trial Group. Effect of HCV RNA suppression during peginterferon alfa-2a


maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterol 137: 1986-

94, 2009. PMC3774149

219. Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC,

Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR,

Dienstag JL and the HALT-C Trial Group. Predicting clinical and histological outcomes

based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterol 138:

136-146, 2010. PMC2813393.

220. Volk ML, Tocco R, Saini S, Lok AS. The Public Health Impact of Antiviral Therapy for

Hepatitis C in the United States. Hepatology 50: 1750-6, 2009. PMID: 19824079

221. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, DiBisceglie AM, Morgan TR,

Kim HY, Lee WM, Bonkovsky HL, Dienstag JL, and the HALT-C Trial Group. Des--

carboxy prothrombin and -fetoprotein as biomarkers for the early detection of

hepatocellular carcinoma. Gastroenterol 138: 493-502, 2010. PMC2819612.

222. Singal AG, Rakoski MO, Salgia R, Pelletier S, Welling TH, Fontana RJ, Lok AS,

Marrero JA. Clinical presentation and prognostic factors for intrahepatic and extrahepatic

cholangiocarcinoma in a tertiary care center. Aliment Pharmacol Ther 31: 625-633, 2010.

PMID: 20003093.

223. Degertekin B, Han SH, Keeffe EB, Schiff ER, Luketic VA, Brown RS, Emre, Soldevila-

Pico C, Reddy KR, Ishitani MB , Tran TT, Pruett TL, Lok ASF, and the NIH HBV-OLT

Study Group. Impact of Virologic Breakthrough and HBIG Regimen on Hepatitis B

Recurrence after Liver Transplantation. Am J Transpl 10: 1823-33, 2010. PMC2910807

224. Fontana RJ, Bieliauskas LA, Back-Madruga C, Lindsay KL, Litman HJ, Lok AS, Kronfol

Z. Cognitive function does not worsen during long-term low-dose peginterferon therapy

in patients with chronic hepatitis C. Am J Gastroenterol 105: 1551-60, 2010.

PMC3772520

226. Delgado-Borrego A, Jordan SH, Negre B, Healey D, Lin W, Kamegaya Y, Christofi M,

Ludwig DA, Lok AS, Chung RT and the HALT-C Trial Group. Reduction of insulin

resistance with effective clearance of hepatitis C infection: results from the HALT-C

Trial. Clin Gastroenterol and Hepatol 8: 458-62, 2010. PMC2856733

227. Lee J, Lok AS, Chen J. Hepatitis B prevalence among Asian Americans in Michigan: an

assessment to guide future education and intervention strategies. J Community Health 35:

534-42, 2010. PMID: 20300810.

228. Chotiyaputta W, Pelletier SJ, Fontana RJ, Lok ASF. Long-term efficacy of nucleoside

monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-

positive donor livers. Hepatol Int; 4: 707-715, 2010. PMC2994614.


229. Volk ML, Piette JD, Singal AS, Lok ASF. Chronic disease management for patients with

cirrhosis. Gastroenterol 139: 14-6, 2010. PMID: 20553725.

230. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of

hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a

systematic review. J Hepatol 53: 348-56, 2010. PMID: 20483498.

231. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, de Santo JL, Lee WM,

DiBisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok ASF, and

the HALT-C Trial Group. Outcome of sustained virological responders in the Hepatitis C

Antiviral Long-term Treatment against Cirrhosis Trial. Hepatology; 52: 833-44, 2010.

PMC2932862

232. Fontana RJ, Dienstag JL, Bonkovsky H, Sterling R, Naishadham D, Goodman Z, Lok A,

Wright E, Su G, and the HALT-C Trial Group. Serum fibrosis markers are associated

with liver disease progression in non-responder patients with chronic hepatitis C. Gut

59:1401-9, 2010. PMC3740000

233. Pockros PJ, Fayez M. Hamzeh FM,

Paul Martin P,

Lentz E, Zhou X, Govindarajan S,

and

Lok AS. Histologic outcomes in hepatitis C-infected patients with varying degrees of

virologic response to interferon-based treatments. Hepatology; 52: 1193-1200, 2010.

PMID: 20658462.

234. Chotiyaputta W, Degertekin B, McKenna BJ, Samala N, Fontana RJ, Lok ASF.

Characteristics of chronic hepatitis B patients who underwent liver biopsies. J Viral

Hepat; 18: 792-803, 2011. PMC3003777

235. Chotiyaputta W, Peterson C, Ditah FA, Goodwin D, Lok ASF. Persistence and adherence

to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol; 54: 12-8, 2011.

PMID: 20888661.

236. Kronfol Z, Litman HJ, Back-Madruga C, Bieliauskas LA, Lindsay KL, Lok AS, Fontana

RJ, and the HALT-C Trial Group. No increase in depression with low-dose maintenance

peginterferon in prior non-responders with chronic hepatitis C. J Affect Disord; 129: 205-

12, 2011. PMC3025085

237. Han SH, Reddy KR, Keeffe EB, Soldevila-Pico C, Gish R, Chung RT, Degertekein B,

Lok A and the NIH HBV OLT Study Group. Clinical outcomes of liver transplantation

for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study. Clin

Transplant; 25: E152-62, 2011. PMC3771871

238. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT,

Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan

TR, and the HALT-C Trial Group. Maintenance peginterferon therapy and other factors

associated with hepatocellular carcinoma in patients with advanced hepatitis C.

Gastroenterol; 140: 840-9, 2011. PMC3057272


239. Volk ML, Reichert HA, Lok ASF, Hayward RA. Variation in organ quality between liver

transplant centers. Am J Transpl; 11: 958-64, 2011. PMC3175797

240. Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR, and the

HALT-C Trial Group. Occult and previous hepatitis B virus infection are not associated

with hepatocellular carcinoma in patients with chronic hepatitis C. Hepatology; 54: 434-

42, 2011. PMC3134544

241. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff

LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS,

Morishima C, Stoddard AM, Everhart JE, for the HALT-C Trial Group. A prospective

study of the rate of progression in compensated, histologically advanced chronic hepatitis

C. Hepatology; 54: 396-405, 2011. PMC3144992

242. Hongthanakorn C, Chotiyaputta W, Oberhelman K, Fontana RJ, Marrero JA, Licari T,

and Lok ASF. Virological breakthrough and resistance in patients with chronic hepatitis

B receiving nucelos(t)ide analogs in clinical practice. Hepatology; 53: 1854-63, 2011.

PMID: 21618260.

243. Chotiyaputta W, Hongthanakorn C, Oberhelman K, Fontana RJ, Licari T, and Lok ASF.

Adherence to nucleos(t)ide analaogues for chronic hepatitis B in clinical practice and

correlation with virological breakthroughs. J Viral Hepat; 19: 205-12, 2012.

244. Huang Y, Tong S, Tai AW, Hussain M, Lok AS. Hepatitis B virus core promoter

mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21.

Gastroenterol 141: 1412-21, 2011. PMC3186859

245. O’Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, Shao Y, Shiffman ML,

Dotrang M, Sninsky JJ, Bonkovsky HL, Pfeiffer RM, and the HALT-C Trial Group. An

IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C.

PLos One 2011; 6:e20904. PMC3132753

246. Qin Y, Tang X, Garcia T, Hussain M, Zhang J, Lok A, Wands J, Li J, Tong S. Hepatitis B

virus genotype C isolates with wild-type core promoter sequences replicate less

efficiently than genotype B isolates but possess higher virion secretion capacity. J Virol;

85: 10167-77, 2011. PMC3766736

247. Rakoski MO, Brown MB, Fontana RJ, Bonkovsky HL, Brunt EM, Goodman ZD, Lok

AS, Omary MB, and the HALT-C Trial Group. Mallory-Denk bodies are associated with

outcomes and histologic features in patients with chronic hepatitis C. Clin Gastroenterol

Hepatol; 9: 902-9, 2011. PMC3400531

248. Ghany MG, Kim H, Stoddard A, Wright EC, Seeff LB, Lok ASF, and the HALT-C Trial

Group. Predicting Clinical Outcomes in Chronic Hepatitis C Using Baseline and Follow-

up Laboratory Data from the Hepatitis C Long-term Treatment Against Cirrhosis Trial.

Hepatology; 54: 1527-37, 2011. PMC3718548


249. Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL,

Lok AS, and the HALT-C Trial Group. Frequency of Elevated Hepatocellular Carcinoma

(HCC) Biomarkers in Patients with Advanced Hepatitis C. Am J Gastroenterol; 107: 64-

74, 2012. PMC3903319

250. Rakoski M, McCammon R, Piette J, Iwashyna T, Marrero J, Lok ASF, Volk M. Burden

of cirrhosis on older Americans and their families: analysis of the Health and Retirement

Study. Hepatology; 55: 184-191, 2012. PMC3462487

251. Volk ML, Tocco RS, Bazick J, Rakoski MO, Lok AS. Hospital Re-Admissions among

Patients with Decompensated Cirrhosis. Am J Gastroenterol; 107: 247-52, 2012.

PMC3470789

252. Snider NT, Weerasinghe SVW, Singla A, Leonard JM, Hanada S, Andrews PC, Lok AS,

Omary MB. Energy determinants GAPDH and NDPK act as genetic modifiers for

hepatocyte inclusion formation. J Cell Biol 195: 217-29, 2011. PMC3198167

253. Curto TM, Lagier RJ, Lok AS, Everhart JE, Rowland CM, Sninsky JJ and the HALT-C

Trial Group. Predicting cirrhosis and clinical outcomes in patients with advanced chronic

hepatitis C with a panel of genetic markers (CRS7). Pharmacogenet Genomics 21: 851-

60, 2011. PMC3215092

254. Dao DY, Hynan LS, Yuan HJ, Sanders C, Balko J, Attar N, Lok ASF, Word A, Lee WM

and the Acute Liver Failure Study Group. Two Distinct Subtypes of Hepatitis B Virus-

Related Acute Liver Failure Are Separable By Quantitative Serum IgM anti-HBc and

HBV DNA Levels. Hepatology; 55: 676-84, 2012. PMC3272543

255. Volk ML, Tocco RS, Pelletier SJ, Zikmund-Fisher BJ, Lok AS. Patient decision making

about organ quality in liver transplantation. Liver Transpl; 13: 1387-93, 2011.

PMC3227783

256. Fontana RJ, Litman HJ, Dienstag JL, Bonkovsky HL, Su G, Sterling RK, Lok AS, for the

HALT-C Trial Group. YKL-40 genetic polymorphisms and the risk of liver disease

progression in patients with advanced fibrosis due to chronic hepatitis C. Liver Int; 32:

665-74, 2011. PMC3299849

257. Ward JW, Lok AS, Thomas DL, El-Serag HB, Kim WR. Report on a single topic

conference on “chronic viral hepatitis – strategies to improve effectiveness of screening

and treatment”. Hepatology; 55: 307-315, 2012. PMID: 22105599.

258. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R,

Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, eley T, Guo T,

Grasela DM, Pasquinelli C. Preliminary study of two antiviral agents for hepatitis C

genotype 1. N Engl J Med; 366: 216-24, 2012. PMID: 22256805.

259. Rao HY, Sun DG, Jiang D, Yang RF, Guo F, Wang JH, Liu F, Zhang HY, Zhang HH, Du

SC, Jin Q, Qin H, Lok AS, Wei L. IL28B genetic variants and gender are associated with


spontaneous clearance of hepatitis C virus infection. J Viral Hepat; 19: 173-81, 2012.

PMID: 22329371.

260. Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, Su GL, Lok AS,

Marrero JA. Effectiveness of hepatocellular carcinoma surveillance in patients with

cirrhosis. Cancer Epidemiol Biomarkers Prev 21: 793-9, 2012. PMID 22374994.

261. Papatheodoridis GV, Manolakopoulos S, Liaw YF, Lok A. Follow-up and indications for

liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently

normal ALT: a systematic review. J Hepatol; 57: 196-201, 2012. PMID 22450396.

262. Thai H, Campo DS, Lara J, Dimitrova Z, Ramachandran S, Xia G, Ganova-Raeva L, Teo

CG, Lok A, Khudyakov Y. Convergence and coevolution of hepatitis B virus drug

resistance. Nature Commun doi: 10.1038/ncomms1794 (2012). PMC3337990

263. Qin S, Zhou Y, Lok AS, Tsodikov A, Yan X, Gray L, Yuan M, Moritz RL, Galas D,

Omenn GS, Hood L. SRM targeted proteomics in search for biomarkers of HCV-induced

progression of fibrosis to cirrhosis in HALT-C patients. Proteomics; 8: 1244-52, 2012.

PMID: 22577025.

264. Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS,

Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC. Reduction in

Hepatic Inflammation Is Associated with Less Fibrosis Progression and Fewer Clinical

Outcomes in Advanced Hepatitis C. Am J Gastroenterol; 107: 1388-98, 2012.

PMC3865099

265. Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, Sievert W, Wong D,

Lovegren M, Cohen D, Llamoso C. Efficacy of Entecavir with or without Tenofovir

Disoproxil Fumarate for Nucleos(t)ide-Naïve Patients with Chronic Hepatitis B.

Gastroenterology 143: 619-628, 2012. PMID: 22643350.

266. Everson GT, Terrault NA, Lok AS, Rodrigo DR, Brown RS, Saab S, Shiffman ML, Al-

Osaimi AMS, Kulik L, Gillespie BW, Everhart JE and the A2ALL Study. A Randomized

Controlled Trial of Pretransplant Antiviral Therapy to Prevent Recurrence of Hepatitis C

after Liver Transplantation. Hepatology; 57: 1752-62, 2013. PMC3510348

267. Kulik LM, Fisher RA, Rodrigo DR, Brown RS, Friese CE, Shaked A, Everhart JE,

Everson GT, Hong JC, Hayashi PH, Berg CL, Lok ASF and the A2ALL Study Group.

Outcomes of Living and Deceased Donor Liver Transplant Recipients with

Hepatocellular Carcinoma: Results of the A2ALL Cohort. Am J Transpl 12:2997-3007,

2012. PMC3523685

268. Kwei K, Tang X, Lok AS, Sureau C, Garcia T, Li J, Wands J, and Tong S. Impaired

Virion Secretion by Hepatitis B Virus Immune Escape Mutants and its Rescue by Wild-

Type Envelope Proteins or a Second-Site Mutation. J Virol; 87: 2352-7, 2013.

PMC3571463


269. Singal AG, NehraM, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, Lok AS, Lee WM.

Detection of Hepatocellular Carcinoma at Advanced Stages among Patients in the HALT-

C Trial: Where Did Surveillance Fail? Am J Gastroenterol; 108: 425-432, 2013. PMID:

23337478.

270. Huang Y, Tai AW, Tong S, Lok AS. HBV core promoter mutations promote cellular

proliferation through E2F1-mediated upregulation of S-phase kinase associated protein 2

transcription. J Hepatol 58: 168-73, 2013. PMC3898818

271. Snider NT, Griggs NW, Singla A, Moons DS, Weerasinghe SV, Lok AS, Ruan C, Burant

CF, Conjeevaram HS, Omary MB. CD73 (ecto-5’-nucleotidas) hepatocyte levels differ

across mouse strains and contribute to Mallory-Denk body formation. Hepatology; 58:

1790-1800, 2013. PMC3796030

272. Chu D, Yang JD, Lok AS, Tran T, Martins EB, Fagan E, Rousseau F, Kim WR. Hepatitis

B screening and vaccination practices in Asian American primary care. Gut Liver 2013;

7: 450-7. PMC3724034

273. Singal AG, Mukherjee A, Elmunzer BJ, Higgins PDR, Lok AS, Zhu J, Marrero JA,

Waljee AK. Machine learning algorithms outperform conventional regression models in

predicting development of hepatocellular carcinoma. Am J Gastroenterol 108:1723-30,

2013. PMID: 24169273.

274. Sharma P, Hosmer A, Appelman H, McKenna B, Jafri M, Sullivan P, Fontana RJ, Lok

AS. Immunologica, dysfunction during or after antiviral therapy for recurrent hepatitis C

reduces graft survival. Hepaol Int 7:990-9, 2013. PMC4371864

275. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KT, Hassanein T, Jacobson I,

Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR. Everson GT,

Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D,

Hindes R, Symonds W, Pasquinelli C, Grasela DM, for the AI44040 Study Group.

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV. N Engl J

Med 370: 211-21, 2014. PMID: 24428467.

276. Lok AS, Gardiner DF, Hezode C, Lawitz EJ, Bourliere M, Everson GT, Marcellin P,

Rodriguez-Torres M, Pol S, Serfaty L, Eley T, Huang SP, Li J, Wind-Rotolo M, Yu F,

McPhee F, Grasela DM, Pasquinelli C. Randomized trial of daclatasvir and asunaprevir

with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol;

60: 490-9, 2014. PMID: 24444658.

277. Hwang JP, Fisch MJ, Lok AS, Zhang H, Vierling JM, Suarez-Almazor ME. Trends in

hepatitis B screening at the onset of chemotherapy in a large US cancer center. BMC

Cancer 13:534.doi:10.1186/11471-2407-13-54, 2013. PMC3827843

278. Terrault NA, Stravitz RT, Lok ASF, Everson GT, Brown RS, Kulik LM, Olthoff KM,

Saab S, Adeyi O, Argo CK, Everhart JE, Rodrigo DR, and the A2ALL Study Group.


Hepatitis C disease severity in living versus deceased donor liver transplant recipients –

an extended observation study. Hepatology 59: 1311-9, 2014. PMC4118586

279. Hwang JP, Suarez-Almazor ME, Torres HA, Palla SL, Huang DS, Fisch MJ, Lok ASF.

Hepatitis C screening in cancer patients receiving chemotherapy. J Oncol Pract 10: e167-

74, 2014. PMC4018458

280. Ghany M, Perrillo R, Li R, Belle SH, Janssen HLA, Terrault NA, Shuhart MC, Lau DTY,

Kim WR, Fried MW, Sterling RK, Di Bisceglie AM, Han SHB, Ganova-Raeva LM,

Chang KM, Lok ASF for the Hepatitis B Research Network (HBRN). The Hepatitis B

Research Network (HBRN): Characteristics of the Adult Cohort in North America

Reflect the Diversity in Country of Origin and Genotype. Clin Gastroenterol Hepatol; 13:

183-92, 2015. PMID 25010003.

281. Wu E, Chen X, Guan Z, Cao C, Rao H Feng B, Chan M, Fu S, Lin A, Wei L, Lok AS. A

comparative study of patients’ knowledge about hepatitis C in the United States and in

urban and rural China. Hepatol Int 8:58-66, 2014. PMID: 25788380.

282. Yapali S, Talaat N, Fontana RJ, Oberhelman K, Lok AS. Outcome of chronic hepatitis B

patients who do not meet criteria for antiviral treatment at presentation. Clin

Gastroenterol and Hepatol; 13: 193-201 2015. PMID: 25041863.

283. Konerman MA, Yapali S, Lok AS. Systematic review: Identifying patients with chronic

hepatitis C in need of early treatment and intensive monitoring - predictors and predictive

models of disease progression. Aliment Pharmacol & Ther; 40: 863-79, 2014. PMID:

25164152.

284. Talaat N, Yapali S, Fontana RJ, Conjeevaram HS, Lok AS. Changes in characteristics of

hepatitis C patients seen in a liver center in the United States during the last decade. J

Viral Hepat 22:481-8, 2015. PMID: 25311830.

285. Wu E, Wang T, Lin T, Chen X, Guan Z, cao C, Rao H, Yang M, Feng B, Pui S, Chan M,

Fu S, Lin A, Wei L, Lok AS. A Comparative Study of Patients’ Attitudes toward Clinical

Research in the United States and Urban and Rural China. Clin Transl Sci; 8: 123-31,

2015. PMID: 25588611.

286. Dan YY, Wong JB, Hamid SS, Han KH, Jia JD, Liu CJ, Piratvisuth T, Lok ASF, Lim

SG. Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia

Pacific countries. Hepatol Int 2014; 8: 382-394.

287. Konerman MA, Zhang Y, Zhu J, Higgins PDR, Lok ASF, Waljee AK. Improvement of

predictive models of risk of disease progression in chronic hepatitis C by incorporating

longitudinal data. Hepatology 61: 1832-41, 2015. PMID: 25684666.

288. Khalili M, Lombardero M, Chung RT, Terrault NA, Ghany MG, Kim WR, Lau D,

Lisker-Melman M, Sanyal A, Lok AS for the HBRN. Diabetes and Prediabetes in Patients


with Hepatitis B Residing in North America. Hepatology 62: 1364-74, 2015. PMID:

26390278.

289. Tayob N, Lok ASF, Do KA, Feng Z. Improved detection of hepatocellular carcinoma

using a longitudinal α–fetoprotein screening algorithm. Clin Gastroenterol Hepatol 14:

469-475, 2016. PMID: 26260109.

290. Patel A, Yapali S, Lok AS. Admissions for hepatitis B reactivation in patients receiving

immunosuppressive therapy remain unchanged from 1999 to 2014. Hepatol Int 10: 139-

146, 2016. PMID: 26272106.

291. Lok AS, McMahon BJ, Brown RS, Wong JB, Ahmed AT, Farah W, Almasri J, Alahdab

F, Benhhadra K, Mouchli MA, Singh S, Mohamed EA. Abu Dabrh AM, Larry PJ, Wang

Z, Murad MH, Mohammed K. Antiviral therapy for chronic hepatitis B virus infection in

adults: a systematic review and meta-analysis. Hepatology; 63: 284-306, 2016. PMID:

26566246.

300. Jonas MM, Lok ASF, McMahon BJ, Brown RS, Wong JB, Ahmed A, Farah W, Mouchli

M, Singh S, Larry PJ, Murad MH, Mohammed K. Antiviral therapy in management of

chronic hepatitis B virus infection in children: a systematic review and meta-analysis.

Hepatology; 63: 307-318, 2016. PMID: 26566163.

301. Ahn J, Lee H, Lim J, Pan C, Nguyen M, Kim WR, Trinh H, Chu D, Tran T, Min A, Do S,

Te H, Reddy R, and Lok A. Entecavir safety and effectiveness in a national cohort of

treatment-naïve chronic hepatitis B patients in the US – the ENUMERATE study.

Aliment Pharmacol Ther; 43: 134-144, 2016. PMID: 26510638.

302. Brown RS, McMahon BJ, Lok ASF, Wong JB, Ahmed AT, Mouchli MA, Wang Z, Larry

PJ, Murad MH, Mohammed K. Antiviral therapy in chronic hepatitis B virus infection

during pregnancy: a systematic review and meta-analysis. Hepatology; 63: 319-333, 2016.

PMID: 26565396.

303. Park JJ, Wong DK, Wahed AS, Lee WM, Feld JJ, Terrault N, Khalili M, Sterling RK,

Kowdley KV, Bzowej N, Lau DT, Kim WR, Smith C, Carithers RL, Torrey KW, Keith

JW, Levine DL, Traum D, Ho S, Valiga M, Johnson GS, Doo E, Lok ASF, Chang KM

for the HBRN. HBV-specific and global T-cell dysfunction in chronic hepatitis B.

Gastroenterol; 150: 684-695, 2016. PMID: 26684441.

304. Konerman MA, Brown M, Zheng Y, Lok ASF. Dynamic prediction of risk of liver-

related outcomes in chronic hepatitis C using routinely collected data. J Viral Hepat 23:

455-463, 2016. PMID: 26893198.

305. Lerrigo R, Beste LA, Leipertz SL, Green PK, Lok ASF, Kogut MJ, Ioannou GN.

Characteristics and outcomes of transjugular intrahepatic portosystemic shunt recipients

in the VA Healthcare system. Eur J Gastroenterol Hepatol 28: 667-675, 2016. PMID:

26886386.


306. Thomson M, Konerman MA, Choxi H, Lok AS. Primary care physician perspectives on

hepatitis C management in the era of direct-acting antiviral therapy. Dig Dis Sci (in press)

2016. PMID: 26957497.

307. Huang J, Guan ML, Balch J, Wu E, Rao H, Lin A, Wei L, Lok AS. Survey of hepatitis B

knowledge and stigma among chronically infected patients and uninfected persons in

Beijing, China. Liver Int; 36:1595-1603, 2016. PMID: 27206379.

308. Lok AS, Pan CQ, Han SB, Trinh HN, Fessel WJ, Rodell T, Massetto B, Lin L, Gaggar A,

Subramanian GM, McHutchison JG, Ferrari C, Lee H, Gordon SC, Gane EJ. Randomized

phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with

chronic hepatitis B. J Hepatol; 65: 509-516, 2016. PMID: 27210427.

309. Yang M, Wu E, Rao H, Du FH, Xie A, Cheng S, Rodd C, Wei L, Lok A. A comparative

study of liver disease care in the United States and Urban and Rural China. Dig Dis Sci;

61: 2847-2856, 2016. PMID: 27256156.

310. Ahn J, Lim JK, Lee HM, Lok AS, Nguyen M, Pan CQ, Mannalithara A, Te H, Reddy

KR, Trinh H, Chu D, Tram T, Lau D, Leduc TS, Min A, Le LT, Bae H, Tran SV, Do S,

Hann HW, Wong C, Han S, Pillai A, Park JS, Tong M, Scaglione S, Woog J, Kim WR.

Lower observed hepatocellular carcinoma incidence in chronic hepatitis B patients treated

with entecavir: results of the ENUMERATE Study. Am J Gastroenterol; 111: 1297-1304,

2016. PMID: 27325221.

311. Gordon FD, Goldberg DS, Goodrich NP, Lok AS, Verna EC, Selzner N, Stravitz RT,

Merion RM. Recurrent PSC in the A2ALL Study: comparison of risk factors between

living and deceased donor recipients. Liver Transpl; 22: 1214-1222, 2016. PMID:

27339253.

312. Levitsky J, Goldberg D, Smith AR, Mansfield SA, Gillespie BW, Merion RM, Lok ASF,

Levy G, Kulik L, Abecassis M, Shaked A. Acute rejection and survival after living or

deceased donor liver transplantation. Clin Gastroenterol Hepatol (in press), 2016. PMID:

27567694.

313. Parikh ND, Marshall VD, Singal AG, Nathan H, Lok AS, Balkrishnan R, Shahinian V.

Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular

carcinoma: an analysis of the SEER-Medicare Database. Hepatology; 65: 122-133, 2017.

PMID: 27770556.

314. Reddy KR, Lim JK, Kuo A, Di Bisceglie AM, Vargas HE, Galati JS, Morelli G, Everson

GT, Kwo PY, Brown RS, Sulkowski MS, Akuschevich L, Lok AS, Pockros PJ, Terrault

NA, Fried MW, Manns MP for the HCV-TARGET Study Group. All-oral, direct-acting

antiviral therapy in HCV-advanced liver disease is effective in real-world practice:

observations through HCV-TARGET database. Aliment Pharm Ther; 45: 115-126, 2017.

PMID. 27790729.


315. Hassan MA, Kim WR, Li R, Smith CI, Fried MW, Sterling RK, Ghany MG, Wahed AS,

Ganova-Raeva LM, Roberts LR, Lok ASF for the Hepatitis B Research Network.

Characteristics of US-born versus foreign-born Americans of African descent with

chronic hepatitis B. Am J Epidemiol (in press) 2017.

316. Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, Kuo A, Lok

AS, Shiffman ML, Ben Ari Z, Akushevich L, Vainorius M, Sulkowski MS, Fired MW,

Nelson DR; HCV-TARGET Study Group. Effectiveness of ledipasvir-sofosbuvir

combination in patients with hepatitis C virus infection and factors associated with

sustained virologic response. Gastroenterol; 151: 1131-1140, 2016. PMID: 27565882.

317. Cheng S, Li E, Lok AS. Predictors and barriers to hepatitis B screening in a Midwest

Suburban Asian population. J Community Health (in press), 2016. PMID: 27770375.

Article I. Invited Editorials/Reviews (peer-reviewed and non peer-reviewed)

1. Thomas HC and Lok ASF. The use of antiviral drugs in chronic hepatitis B virus

infection. Hospital Update Jan. 49-60, 1984.

2. Thomas HC and Lok ASF. The immunopathology of autoimmune and hepatitis B virus

induced chronic hepatitis. Seminars in Liver Disease 4:36-46, 1984.

3. Lok ASF, Lai CL and Lam SK. HBsAg positive patients: What to do? Medical progress

ADIS Press (Guest editorial). 12:7-10, 1985.

4. Lok ASF. Antiviral therapy of chronic hepatitis B virus infection. Journal of

Gastroenterology and Hepatology. 1:169-79, 1986.

5. Lok ASF. Adenine arabinoside and its 5'-monophosphate ester in the treatment of

chronic hepatitis B virus infection. Proceedings of the IXth

International Congress of

Infectious and Parasitic Diseases. Munich July 20-26, 1986. Ed W Margel, W Lang and

E Gabler - Sandberger MMV Medizin Verlag Munchen pp 87-9, 1986.

6. Lok ASF. Update on Management of Chronic Hepatitis B Infection. Philippine J

Microbiology & Infectious Diseases 15:12-5, 1986.

7. Lok ASF. Acute viral hepatitis in chronic carriers of hepatitis B virus: different patterns

in different places. Hepatology 10:252-3, 1989.

8. Lok ASF, Lai CL, W PC, Lau JYN, Leung EKY, Wong LSK. Treatment of chronic type

B hepatitis with interferon: Experience in Asian patients. Sem Liver Dis. 9:249-53,

1989.


9. Lok ASF, Lai CL, Wu PC, Lau JYN, Leung EKY, Wong LSK, Fung YL. Alpha

interferon treatment in Chinese patients with chronic hepatitis B. J Hepatol 11

(Suppl 1):S121-5, 1990.

10. Lok ASF. Hepatitis vaccines. In Current Perspectives in Clinical Hepatology, ed. Jones

DB. Excerpta Medica, Sydney 32-6, 1990.

11. Lok ASF. How should asymptomatic hepatitis B virus carriers be treated? CME Review,

Singapore 1:24-5, 1991.

12. Lok ASF, Lai CL. Treatment of chronic hepatitis B virus infection in children. In

“Therapy in Liver Diseases”, ed. Rodés J and Arroyo V. Doyme SA, Spain pp. 259-66,

1991.

13. Lok ASF. Natural history and control of perinatally acquired hepatitis B virus infection.

Dig Dis 10:46-52, 1992.

14. Lok ASF. Alpha interferon therapy for chronic hepatitis B virus infection in children and

oriental patients. J Gastroenterol & Hepatol 6 (Suppl 1):15-7, 1991.

15. Lok ASF. Hepatitis C: Commentary from Southeast Asia. Medical Progress

19:25,1992.

16. Lok ASF. Antiviral therapy of chronic hepatitis B virus infection. In advances in

hepatology 1990, ed. Wang BE, Yao GB, Yan WY. Shanghai Science and Technology

Press, Shanghai pp: 141-58, 1991.

17. Lok ASF. Hepatitis B vaccination in Hong Kong. J Gastro and Hepatol 8 (Suppl 1):27-

9, 1993.

18. Lok ASF. Chronic hepatitis B virus infection in children. Gastroenterolgia y

Hepatologia 16:391-6, 1993.

19. Lok ASF. Antiviral therapy for the Asian patient with chronic hepatitis B. Sem Liver

Dis 13:360-6, 1993.

20. Lok ASF, Gerber MA. Clinicopathology Conference: A young woman with chronic

hepatitis. Hepatology 17:739-45, 1993.


21. Lok ASF, Soldevila-Pico C. Epidemiology and serologic diagnosis of hepatitis E. J

Hepatol 20:567-9, 1994.

22. Lok ASF, Ghany MG, Gerber MA. Clinicopathology Conference: A young woman with

cirrhosis: Autoimmune hepatitis vs alpha-1-antitrypsin deficiency. Hepatology 19:1302-

6, 1994.

23. Lok ASF. Treatment of chronic hepatitis B. J Viral Hep 1:105-24, 1994.

24. Geders JM, Haque S, Tesi RJ, Gerber MA, Lok ASF. Clinico-pathology conference: A

young man with a solitary hepatic mass. Hepatology 22:655-9, 1995.

25. Lok ASF. Does interferon therapy for chronic hepatitis B reduce the risks of developing

cirrhosis and hepatocellular carcinoma? Hepatology 22:1336-8,1995.

26. McDonnell WM and Lok ASF. Testing for Hepatitis C Virus RNA in Serum: When and

How? Viral Hepatitis Reviews 2:81-3, 1996.

27. McDonnell WM, Lok ASF, Fendrick AM. Diagnostic and treatment strategies in

hepatitis C virus infection. J Clin Outcomes Management 3:15-24, 1996.

28. McDonnell WM, Lok ASF. Viral hepatitis. Current Opinion in Gastroenterology

13:228-234, 1997.

29. Fontana RJ, Lok ASF. Combination therapy for chronic hepatitis B. Hepatology 26:234-

7, 1997.

30. Lok ASF, Gunaratnam NT. Diagnosis of Hepatitis C. Hepatology 26:485-565, 1997.

31. Lok ASF. Prospective study of hepatocellular carcinoma and liver cirrhosis in

asymptomatic chronic hepatitis B virus carriers. Adv Gastroenterology, Hepatology and

Clin Nutr 2:173-175, 1997.

32. Lok ASF. Combination Therapy for chronic hepatitis B. Hepatologia Clinica 6:Suppl 1, 5

51-58, 1998.

33. Chan HLY and Lok ASF. Hepatitis B-clinical perspective: Adults. In Clinics in Liver

Diseases, ed. WM Lee, WB Saunders 3:291-308,1999.

34. Hussain M, Lok ASF. Mutations in Hepatitis B virus polymerase gene associated with


antiviral treatment for hepatitis B. J Viral Hep 6:183-194,1999.

35. Lok ASF. Hepatitis B infection: pathogenesis and management. J. Hepatol 32 (Suppl 1):

78-97,2000.

36. Peters MG, Shouval D, Bonham A, Vierling JM, Lok ASF. Post-transplantation: future

Therapies. Sem Liver Disease 20 (Suppl 1): 19-24, 2000.

37. Lok ASF. Lamivudine Therapy for chronic hepatitis B – is longer duration of treatment

better? Gastroenterology 119: 263-6, 2000. (Editorial)

38. Fontana, RJ, Lok ASF. Lamivudine treatment in patients with decompensated hepatitis B

cirrhosis for whom and when? J. Hepatol 33: 329-332, 2000. (Editorial)

39. Chu CJ, Lok ASF. Does OKT3 increase the risk of recurrent hepatitis B in patients

transplanted for hepatitis B? Liver Transpl. 6:810-812, 2000.

40. Conjeevaram H, Lok ASF. Occult hepatitis B virus infection: A hidden menace.

Hepatology (editorial) 34:204-206, 2001.

41. Lok AS, Heathcote EJ, Hoofnagle JH. Management of Hepatitis B 2000: Report of a

workshop. Gastroenterology 120:1828-1853, 2001.

42. Lok AS, McMahon BJ. AASLD Practice Guideline – Chronic Hepatitis B. Hepatology

34:1225-1241, 2001.

43. Chu CJ, Lok ASF. Clinical utility in quantifying serum DNA levels using PCR assays. J

Hepatol (editorial), 36:549-551, 2002.

44. Chu CJ, Lok ASF. Clinical significance of hepatitis B virus genotypes. Hepatology

(editorial), 35(5):1274-6, 2002.

45. Lok ASF. Perspective on Chronic Hepatitis B. N Engl J Med, 346:1682-3, 2002.

46. Fontana RJ, Lok ASF. Combination of HBIG and Lamivudine resistant mutations: a

formula for trouble? Liver Transplantation 8:1082-4, 2002

47. Fontana RJ, Lok ASF. Non-invasive monitoring of patients with chronic Hepatitis C.

Hepatology 36:S57-64, 2002


48. Lok ASF. Prevention of recurrent Hepatitis B post-liver transplantation. Liver

Transplantation 8:S67-73, 2002

49. Huang MA, Lok AS. Natural history of Hepatitis B and outcome for liver transplantation.

Clin Liver Dis 7:521-536, 2003.

50. Conjeevaram H, Lok AS. Management of Hepatitis B. J Hepatol 38:S90-103, 2003.

51. Wai CT, Lok AS. Treatment of Hepatitis B. J Gastroenterol 37:771-8, 2002.

52. Lok ASF. Hepatitis B: Progress in the last decade. Sem Liver Dis 23:1-4, 2003.

53. Lok ASF. New treatment of chronic hepatitis B. Sem Liver Dis 24 (suppl 1):77-82, 2004.

54. Lok ASF, McMahon BJ. AASLD Practice Guidelines: Hepatitis B, Update of

recommendations. Hepatology. 39:857-861, 2004.

55. Marrero JA, Lok ASF. Occult hepatitis B virus infection in patients with hepatocellular

carcinoma: innocent bystander, cofactor or culprit? Gastroenterology (editorial) 126:347-

350, 2004.

56. Fung SK, Lok ASF. Treatment of Chronic Hepatitis B. Clin Gastro and Hepatol 2:839-

848, 2004.

57. deFranchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, Mele A,

Paumgartner G, Pietrangelo A, Rodes J, Rosenberg W, Valla D – EASL Jury. EASL

International Consensus Conference on Hepatitis B, 13-14 September 2002, Geneva,

Switzerland. J Hepatol 39 (suppl 1): S3-S25, 2003.

58. Fung SK, Lok ASF. Viral Hepatitis 2003. Curr Opin Gastroenterol 20:241-7, 2004.

59. Lok ASF. Prevention of hepatitis B virus-related hepatocellular carcinoma.

Gastroenterology 127 (suppl 1): S303-9, 2004.

60. Marrero JA, Lok ASF. Newer markers of hepatocellular carcinoma. Gastroenterology 127

(suppl 1): S113-9, 2004.

61. Fung SK, Lok ASF. Hepatitis B Virus Genotypes: Do they play a role in outcome of HBV

infection? Hepatology 40:790-2, 2004.


62. Fung SK, Lok ASF. Management of hepatitis B patients with antiviral resistance.

Antiviral therapy 9:1013-26, 2004.

63. Fung SK, Lok ASF. Management of patients with hepatitis B virus-induced cirrhosis. J

Hepatol 42 (suppl 1):S54-64, 2005.

64. Fung SK, Lok ASF. Drug insight: Nucleoside and nucleotide analogue inhibitors for

hepatitis B. Nature Clinical Practice in Gastroenterology and Hepatology 1:90-97, 2004.

65. Lok ASF. Liver Transplantation for Patients with Lamivudine-resistant HBV: What is the

Optimal Prophylactic Strategy? Liver Transpl 11:490-493, 2005.

65. Fung SK, Lok ASF. Update on viral Hepatitis 2004. Curr Opin Gastroenterol 21:300-307,

2005.

66. Lok AS. The maze of hepatitis B treatments. (editorial) N Engl J Med 352:2743-6, 2005.

67. Yim HJ and Lok AS. Natural history of chronic hepatitis B virus infection: what we knew

in 1981 and what we know in 2005. Hepatology 43:S173-S181, 2006.

68. Wong SN and Lok AS. Treatment of hepatitis B: Who, when and how? (editorial) Arch

Intern Med (editorial) 166:9-12, 2006.

69. Wong SN and Lok AS. Update on Viral Hepatitis: 2005. Curr Opin Gastroenterol

22:241-7, 2006.

70. Osborn MK and Lok AS. Antiviral options for the treatment of chronic hepatitis B. J

Antimicrob Chemother 57:1030-4, 2006.

71. Sharma P and Lok A. Viral Hepatitis and Liver Transplantation. Semin Liver Dis 26:285-

297, 2006.

72. Wong SN and Lok AS. Tenofovir disoproxil fumarate: role in hepatitis B treatment.

Hepatology (editorial) 44:309-313, 2006.

73. Kang H and Lok AS. Endpoints for clinical trials on treatment of hepatitis C. J Hepatol

(editorial) 45:473-5, 2006.

74. Tan J and Lok AS. Antiviral Therapy for Pre- and Post- Liver Transplantation Patients


with Hepatitis B. Liver Transpl (editorial) 13:323-6, 2007.

75. Lok ASF, McMahon BJ. AASLD Practice Guidelines: Hepatitis B. Hepatology 45:507-

539, 2007. Corrections Hepatology 45:1347, 2007.

76. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok ASF. Management of Hepatitis B:

Summary of a Clinical Research Workshop. Hepatology 45:1056-67, 2007.

77. Tan J and Lok AS. Update on Viral Hepatitis 2006. Curr Opin Gastro 23: 263-7, 2007.

78. Lok AS. Navigating the Maze of Hepatitis B Treatments. Gastroenterology 132:1586-94,

2007.

79. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany M, Pawlotsky JM, Liaw YF,

Mizokami M, Kuiken C. Antiviral drug-resistant HBV: Standardization of nomenclature

and assays and recommendations for management. Hepatology 46:254-265, 2007.

80. Degertekin B and Lok AS. When to start and stop hepatitis B treatment: can one set of

criteria apply to all patients regardless of age at infection? Annals Intern Med 147:62-64,

2007.

81. Zoulim F, Buti M, Lok AS. Antiviral-resistant hepatitis B virus: can we prevent this

monster from growing? J Viral Hepat 14: (suppl 1): S29-36, 2007.

82. Degertekin B and Lok AS. Monitoring antiviral resistance in patients receiving

nucleos/tide analogue therapies for hepatitis B: which method should be used? J Hepatol

48: 892-4, 2008. PMID: 18433924

83. Degertekin B and Lok AS. Update on Viral Hepatitis 2007. Curr Opin Gastroenterol 24:

306-311, 2008. PMID: 18408458

84. Llovet JM and Lok A. Hepatitis B virus genotype and mutants: risk factors for

hepatocellular carcinoma. JNCI (editorial) 100:1121-3, 2008. PMC2720710

85. Lok ASF. How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver

transplant setting? Liver Transpl; 14 (suppl 2): S8-S14, 2008. PMID: 18825720

86. Chotiyaputta W and Lok AS. Role of antiviral therapy in the prevention of perinatal

transmission of HBV infection. J Viral Hepat 16: 91-3, 2009. PMID: 18165766


87. Volk ML and Lok AS. Is family history of liver cancer a risk factor for hepatocellular

carcinoma? J Hepatol 50:247-8, 2009. PMID: 19070916

88. Degertekin B and Lok AS. What is the optimal regimen for preventing hepatitis B

recurrence after liver transplantation? Nature Clin Pract Gastroenterol Hepatol 6:68-9,

2009. PMID: 19092788

89. Degertekin B and Lok AS. Update on Viral Hepatitis 2008. Curr Opin Gastroenterol 25:

180-5, 2009. PMID: 19387254

90. Lok ASF. Evolution of nucleoside/tide analogues for hepatitis B: is the ideal drug here

yet? J Hepatol 51: 416-8, 2009. PMID: 19410323

91. Degertekin B and Lok ASF. Indications for therapy in hepatitis B. Hepatology 49: S129-

137, 2009. PID: 19399799

92. Afdhal NH, Lok AS, Di Bisceglie AM. Clinical decisions. Management of incidental

hepatitis C virus infection. N Engl J Med 360: 1902-6, 2009. PMID: 19403909

93. Chotiyaputta W and Lok ASF. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol

6: 453-462, 2009. PMID: 19581904

94. Fleischer RD and Lok ASF. Myopathy and Neuropathy associated with Nucleos(t)ide

Analog Therapy for Hepatitis B. J Hepatol 51:787-91, 2009. PMID: 19665816

95. Lok AS. Hepatitis B: liver fibrosis and hepatocellular carcinoma. Gastroenterol Clin Biol

33: 911-5, 2009. PMID: 19577871

96. Lok AS and McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 50: 661-2,

2009. PMID: 19714720

97. Lok AS. EASL International Awardee 2009: Professor Ding-Shinn Chen. J Hepatol 51:

615-6, 2009. PMID: 19760808

98. Lok AS. Should antiviral treatment be extended to patients with chronic hepatitis B and

mildly elevated alanine aminotransferase? Hepatology (editorial) 51: 1107-9, 2010.

PMID: 20162620.

99. Jafri SMR and Lok AS. Antiviral therapy for chronic hepatitis B. Clinics in Liver Dis 14:

425-38, 2010. PMID: 20638023.


100. El-Serag H, Lok AS, Thomas DL. The dawn of a new era: transforming our domestic

response to hepatitis B and C. Gastroenterol 138:1225-30, 2010. PMID: 20176024.

101. Lok ASF, Kim WR, El-Serag H, Maddrey WC. The dawn of a new era: transforming our

domestic response to hepatitis B & C – activity 1: Overview of the viral hepatitis

problem. J Family Practice 59 (supplement): S11-6, 2010. PMID: 20398585.

102. Chotiyaputta W and Lok ASF. Endpoints of hepatitis B treatment. J Viral Hepat 17: 675-

84, 2010. PMID20840331.

103. Lok AS. Diagnostic and Therapeutic Advances in Hepatology – Drug therapy: Tenofovir.

Hepatology; 52: 743-7, 2010. PMID: 20597070.

104. Hongthanakorn C and Lok ASF. New Pharmacological Therapies in Chronic Hepatitis B.

Gastroenterol Clinics of N America; 39: 659-680, 2010. PMID:20951923.

105. Brunetto MR, Lok AS. New approaches to optimize treatment response in chronic

hepatitis B. Antivir Ther; 15 (suppl 3): 61-8, 2010. PMID: 21041905.

106. Lok AS. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma? J

Gastroenterol Hepatol 26: 221-7, 2011. PMID: 21070361.

107. Huang Y and Lok AS. Viral factors and outcomes of chronic HBV infection. Am J

Gastroenterol (editorial) 106: 93-5, 2011. PMID: 21212756.

108. Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol; 8: 275-84, 2011.

PMID 21423260.

109. Lok AS. Authorship: Who should be included and how should it be determined?

Gastroenterol; 141: 786-8, 2011. PMID: 21782816.

110. Hatzakis A, Wait S, Bruix J, Buti M, Caballo M, Cavaleri M, Colombo M, Delarocque-

Astagneau E, Dusheiko G, Esmat G, Esteban R, Goldberg D, gore C, Lok ASF, Manns

M, Marcellin P, Papatheodoridis G, Peterle A, Prati D, Piorkowsky N, Rizzetto M,

Rodot-Thoraval F, Soriano V, Thomas HC, Thursz M, Valla D, van Damme P,

Veldhuijzen IK, Wedemeyer H, Wiessing L, Zanetti AR, and Janssen HLA. The state of

hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral

Hepat 18 (Suppl 1): 1-16, 2011. PMID: 21824223.

111. Kwon H, Lok AS. Does antiviral therapy prevent hepatocellular carcinoma? Antivir Ther;

16: 787-95, 2011. PMID: 21900710.


112. Sharma P, Lok AS. Interferon-free treatment regimens for hepatitis C: are we there yet?

Gastroenterol 141: 1963-7, 2011. PMID: 22033188.

113. Scaglione SJ, Lok AS. Effectiveness of Hepatitis B Treatment in Clinical Practice.

Gastroenterol 142: 1360-8, 2012. PMID: 22537444.

114. Mutimer D, Lok ASF. Management of HBV and HCV Induced End Stage Liver Disease.

Gut; 61 (suppl 1): i59-i67, 2012. PMID: 22504920.

115. Lok AS, Pawlotsky JM. Viral hepatitis at a crossroad. Gastroenterol 142: 1261-3, 2012.

PMID: 22537431.

116. Lok ASF, Ward JW, Perrillo RP, McMahon BJ, Liang TJ. Reactivation of hepatitis B

during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med;

156: 743-5, 2012. PMC3469313

117. Lok ASF. Does antiviral therapy prevent recurrence of hepatitis B virus related

hepatocellular carcinoma after curative liver resection? (invited editorial) JAMA 308:

1922-4, 2012. PMID: 23147511.

118. Lok ASF. HCV NS5A Inhibitors in Development. Clin Liver Dis 17: 111-121, 2013.

119. Lok AS. Long-term therapy of chronic hepatitis B reverses cirrhosis. Nature Rev

Gastroenterol & Hepatol; 10: 199-200, 2013. PMID: 23358397.

120. Kanwal K, Lok AS, El-Serag HB. CDC and USPSTF 2012 Recommendations for

Screening for Hepatitis C Virus Infection: Overview and Take-Home Messages.

Gastroenterol; 144: 478-81, 2013. PMID: 23419454. Clin Gastroenterol Hepatol; 11:

200-3, 2013. PMID: 23432900.

121. Lok AS. Combination nucleos(t)ide analogues as initial treatment for chronic hepatitis B:

Have we put this to rest? (invited editorial) Hepatology 58:483-5, 2013. PMID:

23423734.

122. Yapali S, Talaat N, Lok AS. Management of Hepatitis B: Our Practice and how it relates

to the Guidelines. Clin Gastroenterol Hepatol 12: 16-26, 2014. PMID: 23660419.

123. Yapali S, Lok AS. Should treatment of hepatitis B patients be based solely on liver

fibrosis? Clin Gastroenterol Hepatol, 11: 1500-2, 2013. PMID: 23891926.

124. Hwang JP and Lok ASF. Management of patients with hepatitis B who require


immunosuppressive therapy. Nature Rev Gastroenterol & Hepatol 11: 209-19, 2014.

PMC4170710

125. Yapali S and Lok AS. Potential benefit of telbivudine on renal function does not

outweigh its high rate of antiviral drug resistance and other adverse effects. Gastroenterol

(invited editorial) 146: 15-9, 2014. PMID: 24275236.

126. Trepo C, Chan HLY, Lok A. Hepatitis B virus infection. Lancet; 384: 2053-63, 2014.

PMID: 24954675.

127. Wei L and Lok ASF. Impact of new hepatitis C treatments in different regions of the

world. Gastroenterol 146:1145-50, 2014. PMID: 24662488.

128. Lok ASF. Progress in hepatitis B: a 30-year journey through three continents. Hepatology

60: 4-11, 2014. PMID: 24619499.

129. Yapali S and Lok AS. Does suppression of HBV replication by antiviral therapy confer

the same benefit as host immune control of HBV? Gut (invited editorial) 63:1833-4,

2014. PMID: 24691291.

130. Konerman MA and Lok AS. Diagnostic challenges of hepatitis C. JAMA 311: 2536-7,

2014. PMC4250928

131. Konerman MA and Lok AS. Is it more cost effective for patients with chronic hepatitis B

to have a trial of interferon before considering nucleos(t)ide analogue therapy? Clin

Gastroenterol and Hepatol (invited editorial) 13: 386-9, 2015. PMID 25158927.

132. Di Bisceglie AM, Lok AS, Martin P, Terrualt N, /Perrillo RP, Hoofnagle JH. Recent FDA

warnings on hepatitis B reactivation with immune-suppressing and anti-cancer drugs: Just

the tip of the iceberg? Hepatology 61: 703-711, 2015. PMID: 25412906.

133. Perrillo RP, Martin P, Lok AS. Preventing hepatitis B reactivation due to

immunosuppressive drug treatments. JAMA 313: 1617-8, 2015. PMID: 25790287.

134. Lok AS. Personalized treatment of hepatitis B. Clin Mol Hepatol 21: 1-6, 2015.

PMV4379190

135. Locarnini S, Hatzakis A, Chen DS, Lok AS. Strategies to control hepatitis B: public

policy, epidemiology, vaccine and drugs. J Hepatol; 62 (1S):S76-S86, 2015. PMID:

25920093.

136. Lok AS. Hepatitis B: 50 years after the discovery of Australia antigen. J Viral Hepat 23:


5-14, 2016. PMID: 26280668.

137. Liang TJ, Block TM, McMahon BJ, Ghany MG, Urban S, Guo JT, Locarnini S, Zoulim

F, Chang KM, Lok AS. Present and future therapies of hepatitis B: From discovery to

cure. Hepatology; 62: 1893-1908, 2015. PMID: 26239691.

138. Konerman MA and Lok AS. Interferon treatment for hepatitis B. Clin Liver Dis; 20: 645-

665, 2016. PMID: 27742005.

139. Konerman MA and Lok AS. Hepatitis C treatment and barriers to disease eradication.

Clin Transl Gastroenterol; 7 (9): e193, 2016. PMID: 27657495.

Books

1. Sherlock’s Diseases of the Liver and Biliary System, ed. J Dooley, AS Lok, AK

Burroughs, EJ Heathcote. Wiley, 12th

edition, 2011.

2. Viral Hepatitis, ed. Thomas HC, Lok ASF, Locarnini SA, Zuckerman AJ. Wiley

Blackwell, 4th

edition, 2013.

Guest Editor

1. Lok ASF, Villamil FG, McDiarmid SV. Liver Transplantation for Viral Hepatitis. Liver

Transplantation, Vol 8, no. 10, supplement; 2002

2. Lok ASF. Hepatitis B. Seminars in Liver Disease Volume 23, number 1, 2003

3. Lok ASF and Schiff ER. The dawn of a new era: transforming our domestic response to

hepatitis B & C. J Family Practice Volume 59, number 4 (supplement), 2010.

Chapters in Books

1. Thomas HC and Lok ASF. Approaches to the treatment of chronic hepatitis B virus

infection. In Advances in Hepatitis Research, ed. Chisari F, Massons Publishing Inc.

27:241-50.

2. Thomas HC and Lok ASF. Treatment of chronic hepatitis B virus infection. In Delta

infection and Viral Hepatitis, ed. Verme G, Bonino F and Rizzetto M, Alan R Liss Inc.

pp: 379-96.

3. Lai CL, Wu PC, Yeoh EK, Lok ASF, Lin HJ, Lam SK and Todd D. Hepatocellular

Carcinoma and the Hepatitis B Virus. In Viral Hepatitis Infection in the Western Pacific


Region: Vaccine and control, ed. Lam SK, Lai CL and Yeoh EK. World Scientific Pub;

pp: 3-18.

4. Davis GL, Lok ASF, Schiff ER. Special issues in the treatment of chronic viral hepatitis

with alpha interferon. In Viral Hepatitis and Liver Disease, ed. Hollinger FB, Lemon SM,

Margolis HS, Williams and Wilkins, Baltimore pp: 823-7, 1991.

5. Lok ASF. Interferon therapy in chronic hepatitis B. In “Update on gastrointestinal and

hepatobiliary disorders”, ed. Kurathong S, Wongpaitoon V, Akarawong K. Bangkok

Medical Publisher, Thailand pp: 12-23, 1992.

6. Geders JM, Lok ASF. Interferon therapy for atypical or unusual patients with chronic

viral hepatitis. In Therapy of Liver Diseases, ed. J Rodes and V Arroyo, Masson-Little,

Brown and Co. pp: 187-94, 1995.

7. Lok ASF, Bozkaya H, Ayola B. Hepatitis B virus pre-core/core gene mutants:

epidemiology. In Viral Hepatitis and Liver Disease, ed. M Rizzetto. Purcell RH, Genin

JH, Venne G, Edizoni Minerva Medila, Turin, pp 104-107, 1997.

8. Negro F, Lok ASF. Chronic Viral Hepatitis. In Clinical Practice of Gastroenterology. ed.

LJ Brandt. Current Medicine Inc., Churchill Livingstone, Ch 94, pp 839-848, 1998.

9. Chan HLY, Ghany MG, Lok ASF. Hepatitis B In “Schiff’s Diseases of the Liver”, ed. ER

Schiff, M Sorrell, W Maddrey. Lippincott-Raven Press., 8th

edition Ch 29, pp 757-792,

1998.

10. Chan HLY and Lok ASF. Viral hepatitis B and D. In ‘Principles of Clinical Hepatology’

ed. O’Grady J, Lake J, Howdle P. Harcourt Publishers, Ch. 3 pp 121-122, 2000.

11. Lok ASF. Treatment of chronic hepatitis B virus infection. In Therapy of Liver Diseases,

ed. J Rodes and V Arroyo, Masson-Little, Brown and Co. pp 261-268, 1999.

12. Hussain KB, Lok ASF. Hepatitis B Virology: Acute and Chronic Infection-Wild type

HBV and HBV variants. In Viral Hepatitis ed. S. Gordon, Marcel Dekker Inc. Ch 1, pp 1-

32, 2001.

13. Teo EK, Lok ASF. Treatment of Chronic hepatitis B. In Chronic Viral Hepatitis, ed. R

Koff, G Wu, Humana Press Inc. Ch 7, pp 123-144, 2001.


14. Lok ASF. Treatment of hepatitis B e antigen position, chronic hepatitis. In Viral Hepatitis

ed. M. Buti, R Esteban, J Guardia, Accion Medica, Spain, pg 47-56, 2000.

15. Fontana RJ, Lok ASF. Hepatitis B. In Evidence-Based Gastroenterology, ed. EJ Irvine

and RH Hunt, BC Decker, Hamilton, Canada, Ch 27, pp 377-394, 2001.

16. Lok ASF. New Treatment of Chronic Hepatitis B. Therapy in Hepatology, ed. V Arroyo,

P Gines, J Bosch, M Navara, J Bruix, and J Rodes. An Medica, Spain, pp 245-250, 2001.

17. Lok ASF, Conjeevaram H. Hepatitis B In Schiff’s Diseases of the Liver, ed. ER Schiff, M

Sorrell, W Maddrey. Lippincott, Williams and Wilkins, 9th

Edition, Ch. 27, pg 763-806,

2002.

18. Lok ASF. New treatment of chronic hepatitis B. In Viral Hepatitis, ed. M Buti, R

Esteban. Accion Medica, Spain, pg 59-66, 2003.

19. Lok ASF. Treatment of Chronic Hepatitis B – 2003. In Progress in the Treatment of Liver

Diseases, ed. Arroyo V, Forns X, Garcia-Pagan JC, Rodes J. Ars Medica, Spain, pg 113-

120, 2003.

20. Lok ASF. Is viral clearance a realistic goal in the treatment of chronic viral hepatitis. In

Viral Hepatitis and Liver Disease, ed. Jilbert AR, Grgacic EV, Vickery K, Burrell CJ,

Cossart YE. Australian Centre for Hepatitis Virology, pg 156-162, 2004.

21. Marrero JA, Lok AS. Primary Hepatic Neoplasm. In Advanced Therapy in

Gastroenterology and Liver Disease, ed. Bayless and Diehl. B.C. Decker, Hamilton,

Canada, pg 732-8, 2005.

22. Lok ASF, Conjeevaram H and Negro F. Hepatitis B and D. In Schiff’s Diseases of the

Liver, ed. ER Schiff, M Sorrell, W Maddrey. Lippincott, Williams and Wilkins, 10th

Edition Ch 29, pg 745-806, 2006.

23. Degertekin B and Lok ASF. Management of Patients with Antiviral Drug-Resistant HBV.

In Viral Hepatitis, ed. M Buti and R Esteban, pg 130-141, 2008.

24. Lemon SM, Lok A, and Alter MJ. Viral Hepatitis. In Sexually Transmitted Diseases. ed.

K. Holmes, P. Sparling, W. Stamm, P. Piot, J. Wasserheit, L. Corey, M. Cohen, D. Watts.

McGraw Hill, pg 509-543, 2008.

24. Lok ASF and Negro F. Hepatitis B and D. In Schiff’s Diseases of the Liver, ed. ER


Schiff, M Sorrell, W Maddrey. Wiley, 11th

edition, Chapter 24, pg 537-581, 2011.

25. Lok ASF. Hepatitis B. In Sherlock’s Diseases of the Liver and Biliary System, ed. J

Dooley, AS Lok, AK Burroughs, EJ Heathcote. Wiley, 12th

edition, Chapter 18, pg 367-

392, 2011.

26. Conjeevaram HS and Lok AS. Hepatitis B and C in non-liver transplant patients. In

Zakim and Boyer’s Hepatology: A Textbook of Liver Diseases. Elsevier, 6th

edition,

Chapter 39, pg 700-717, 2011.

27. Kwon HK and Lok ASF. Treatment of Hepatitis B. In Viral Hepatitis, ed. Thomas HC,

Lok ASF, Locarnini SA, Zuckerman AJ. Wiley Blackwell, 4th edition, Chapter 14, pg

188-202, 2013.

28. Konerman MA and Lok AS. Epidemiology, Diagnosis and Natural History of Hepatitis B.

In Zakim and Boyer’s Hepatology: A Textbook of Liver Diseases. Elsevier, 7th

edition,

eds A Sanyal, N Terrault and K Lindor, Chapter 32, 2016 (in press).

On-Line Publications / Audio-Visual

Uptodate

AV1. Negro F., Lok ASF. Diagnosis of hepatitis D virus infection.

AV2. Negro F, Lok ASF. Pathogenesis and clinical manifestations of hepatitis D virus

infection.

AV3. Negro F, Lok ASF. Treatment and prevention of hepatitis D virus infection.

AV4. Lok ASF. Hepatitis D virus infection following liver transplantation.

AV5. Lok ASF. Standard and pegylated interferon therapy for chronic hepatitis B virus

infection.

AV6. Lok ASF. Liver transplantation for chronic hepatitis B.

AV7. Lok ASF. Investigational treatment of chronic hepatitis B.

AV8. Lok ASF. Clinical manifestations and natural history of hepatitis B virus infection.

AV9. Teo EK, Lok ASF. Epidemiology, transmission and prevention of hepatitis B virus

infection.

AV10. Lok ASF. Serologic diagnosis of hepatitis B.

AV11. Lok ASF. Characteristics of the hepatitis B virus and pathogenesis of infection.

AV12. Chan TM, Lok ASF. Renal diseases associated with hepatitis B virus infection.

AV13. Lok ASF. Lamivudine monotherapy in the treatment of chronic hepatitis B.

AV14. Teo EK, Lok ASF. Hepatitis B Vaccination

AV15. Chu, CJ, Lok, ASF. Clinical significance of HBV genotypes.

AV16. Chu, CJ, Lok, ASF. Clinical significance and molecular characteristics of common HBV


variants.

AV17. Lok ASF. Adefovir dipivoxil treatment of chronic hepatitis B.

AV18. Lok ASF. Combination therapy of chronic hepatitis B.

AV19. Lok ASF. Entecavir in the treatment of chronic hepatitis B.

AV20. Lok ASF. Telbivudine in the treatment of chronic hepatitis B.

AV21. Lok ASF. Tenofovir in the treatment of adults with chronic HBV infection who do not

have HIV infection.

AV22. Lok ASF and Bonis P. HBV reactivation associated with immunosuppression.

AV23. Lok ASF. Overview of the management of hepatitis B and case examples.

AV24. Rose BD and Lok ASF. Hepatitis B virus and renal transplant recipients.

AV25. Lee H and Lok ASF. Hepatitis B and pregnancy.

Clinical Liver Disease

Editor: Hepatitis B, Volume 2, Issue 1, 2013

Lok ASF. New all-oral HCV therapies for genotype 1: a final good-bye to interferon, 2014.

Kwon H and Lok AS. Viral Hepatitis and Pregnancy, 2014.

anna suk-fong lok, m.d., f.r.c.p., agaf, faasld alice ...consulting positions page 15 visiting...

Documents